Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.

584 recruiting in this ClinicalTrials.gov snapshot · reviewed 2026-08-17

ALS clinical trials, in English

ALS (amyotrophic lateral sclerosis) studies often require a recent diagnosis window, a breathing (FVC) threshold, and a stable riluzole or edaravone regimen. Genetic subtypes such as SOD1 have their own records. This hub is a registry snapshot, not an ALS clinic. Sourced from ClinicalTrials.gov. Not a recommendation to join any study.

How to read this list

Each headline is a rewrite of registry fields (phase, intervention, condition). Open the NCT link before you call a site. Eligibility is decided by the study team, not by this page. See how to find a trial and eligibility explained.

Phases in this snapshot: Not a traditional drug phase (316) · Phase 3 (73) · Phase 2 (72) · Phase 1 (42) · Phase 4 (32) · Phase 1 / Phase 2 (31) · Phase 2 / Phase 3 (10) · Early phase 1 (8)

Cities that appear on these records

  • New York, New York · 138
  • Seoul, South Korea · 134
  • Madrid, Spain · 96
  • Houston, Texas · 94
  • Bethesda, Maryland · 90
  • Chicago, Illinois · 88
  • Barcelona, Spain · 77
  • St Louis, Missouri · 74

Browse by US state · city hubs

Intervention hubs that overlap this snapshot: Pembrolizumab · Ketamine · Empagliflozin · Tirzepatide · Psilocybin · Semaglutide

RecruitingNot a traditional drug phaseBethesda, Maryland
Study of Systemic Lupus Erythematosus

This protocol will evaluate patients with systemic lupus erythematosus (SLE) and their relatives to learn more about how the disease develops and changes over time. It will also study genetic factors that make a person susceptible to SLE.

NCT00001372 · Official ClinicalTrials.gov record · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

RecruitingNot a traditional drug phaseWashington D.C., District of Columbia
Familial Mediterranean Fever and Related Disorders: Genetics and Disease Characteristics

This study is designed to explore the genetics and pathophysiology of diseases presenting with intermittent fever, including familial Mediterranean fever, TRAPS, hyper-IgD syndrome, and related diseases. The following individuals may be eligible for this natural history study: 1) patients with known or suspected familial Mediterranean fever, TRAPS, hyper-IgD syndrome or related disorders; 2) relatives of these patients; 3) healthy, normal volunteers 7 years of age or older.

NCT00001373 · Official ClinicalTrials.gov record · National Human Genome Research Institute (NHGRI)

RecruitingNot a traditional drug phaseBethesda, Maryland
Evaluation of Patients With HAM/TSP

Objective: Human T-lymphotropic virus type-I-associated myelopathy / tropical spastic paraparesis (HAM/TSP) is a rare neurologic disorder that affects less than 5% of patients infected with the HTLV-I virus. The purpose of this protocol is to study the natural history of HAM/TSP by monitoring clinical progression of patients longitudinally.

NCT00001778 · Official ClinicalTrials.gov record · National Institute of Neurological Disorders and Stroke (NINDS)

RecruitingNot a traditional drug phaseBethesda, Maryland
Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease

Selected individuals suspected of having or with prior biopsy proof of malignant disease will be seen in the Urologic Oncology Branch, NCI. Blood samples may be collected at the time of the initial visit and at periodic intervals during the course of the disease.

NCT00026884 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)

RecruitingNot a traditional drug phaseBethesda, Maryland
Genetic Analysis of Birt Hogg-Dube Syndrome and Characterization of Predisposition to Kidney Cancer

This study will investigate the genetic cause of Birt Hogg-Dube (BHD) syndrome and the relationship of this disorder to kidney cancer. BHD is a rare inherited condition characterized by papules, or bumps-benign tumors involving hair follicles-on the head and neck.

NCT00033137 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)

RecruitingNot a traditional drug phaseBethesda, Maryland
Evaluation of Patients With Immune Function Abnormalities

This study will evaluate patients with abnormal immune function that results in recurrent or unusual infections or chronic inflammation. This may include inherited conditions, such as X-linked severe combined immunodeficiency (XSCID), chronic granulomatous disease (CGD), and leukocyte adhesion deficiency (LAD), or conditions resulting from outside factors, such as graft-versus-host disease (GVHD).

NCT00128973 · Official ClinicalTrials.gov record · National Institute of Allergy and Infectious Diseases (NIAID)

RecruitingNot a traditional drug phaseWashington D.C., District of Columbia
Natural History Study of Patients With Excess Androgen

This study will evaluate and gather information in patients with genetic causes of too much androgen (male-like hormone) in order to better understand the effects of too much androgen and describe problems associated with it. Too much androgen in childhood, if untreated, results in rapid growth and early puberty with early cessation of growth and short stature in adulthood.

NCT00250159 · Official ClinicalTrials.gov record · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

RecruitingNot a traditional drug phaseBethesda, Maryland
Blood Sampling for Research Related to Sickle Cell Disease

This study will collect representative blood samples from healthy children and adults and from children and adults who have unique red blood cell features that are related to sickle cell disease. Sickle cell disease is a blood disease that limits the ability of red blood cells to carry oxygen throughout the body.

NCT00542230 · Official ClinicalTrials.gov record · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

RecruitingNot a traditional drug phaseBethesda, Maryland
Studies of Skin Microbes in Healthy People and in People With Skin Conditions

This study will examine microbes (e.g., bacteria, fungi, viruses) that live on human skin and how microbes contribute to health and disease. It will analyze healthy human skin and how the these microorganisms might change in patients with atopic dermatitis (AD), a skin condition also known as eczema.

NCT00605878 · Official ClinicalTrials.gov record · National Human Genome Research Institute (NHGRI)

RecruitingNot a traditional drug phaseBethesda, Maryland
Clinical and Immunologic Monitoring of Patients With Known or Suspected HIV Infection

This study will investigate HIV infection and associated conditions by monitoring infected patients. The study will also serve as a means for recruiting HIV-infected individuals to NIAIDs ongoing clinical and laboratory studies and supporting the institute s infectious disease training program by providing Infectious Disease fellows with ongoing training in the management of HIV infection.

NCT00789009 · Official ClinicalTrials.gov record · National Institute of Allergy and Infectious Diseases (NIAID)

RecruitingNot a traditional drug phaseBethesda, Maryland
Comprehensive Multimodal Analysis of Neuroimmunological Diseases of the Central Nervous System

Inflammatory or degenerative diseases of the brain and spinal cord, such as multiple sclerosis, may be related to problems with an individual s immune system. However, more information is needed on the ways in which the cells of the immune system interact with the central nervous system (CNS).

NCT00794352 · Official ClinicalTrials.gov record · National Institute of Allergy and Infectious Diseases (NIAID)

RecruitingNot a traditional drug phaseBethesda, Maryland
Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocy…

Background The development of new technologies now allow scientists to investigate the molecular basis and clinical manifestations of monoclonal B cell lymphocytosis (MBL), chronic lymphocytic leukemia(CLL)/small lymphocytic lymphoma (SLL), lymphoplasmacytic lymphoma (LPL)/Waldenstrom macroglobulinemia (WM), and splenic marginal zone lymphoma (SMZL). Applying these methods in a natural history study can help identify processes involved in disease progression, and possibly lead to the discovery or validation of treatment targets.

NCT00923507 · Official ClinicalTrials.gov record · National Heart, Lung, and Blood Institute (NHLBI)

RecruitingNot a traditional drug phaseBethesda, Maryland
Surgery as a Treatment for Medically Intractable Epilepsy

Background: \- Drug resistant epilepsy is the term used to describe epilepsy that cannot be controlled by medication. Many people whose seizures do not respond to medication will respond to surgical treatment, relieving seizures completely or almost completely in one-half to two-thirds of patients who qualify for surgery.

NCT01273129 · Official ClinicalTrials.gov record · National Institute of Neurological Disorders and Stroke (NINDS)

RecruitingNot a traditional drug phaseBethesda, Maryland
Cell Collection to Study Eye Diseases

Background: \- Best Vitelliform Dystrophy (Best disease), Late-Onset Retinal Degeneration (L-ORD), and Age-Related Macular Degeneration (AMD) all affect the retina, the light sensing area at the back of the eye. Doctors cannot safely obtain retinal cells to study these diseases.

NCT01432847 · Official ClinicalTrials.gov record · National Eye Institute (NEI)

RecruitingNot a traditional drug phaseBethesda, Maryland
Not a traditional drug phase: Medtronic Activa Tremor Control System for Parkinson's Disease

Background: \- Deep brain stimulation (DBS) is an approved surgery for certain movement disorders, like Parkinson's disease, that do not respond well to other treatments. DBS uses a battery-powered device called a neurostimulator (like a pacemaker) that is placed under the skin in the chest.

NCT01581580 · Official ClinicalTrials.gov record · National Institute of Neurological Disorders and Stroke (NINDS)

RecruitingNot a traditional drug phaseSioux Falls, South Dakota
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford

The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research. Individuals affected by rare diseases, undiagnosed conditions, and disorders of unknown prevalence may voluntarily contribute health information to support natural history studies, participant recruitment, and other research efforts.

NCT01793168 · Official ClinicalTrials.gov record · Sanford Health

RecruitingNot a traditional drug phaseBethesda, Maryland
Tumor Related Epilepsy

Background: Some people with brain tumors have seizures related to the tumor. Usually brain tumors are treated by removing as much of the brain tumor as possible without causing problems.

NCT02639325 · Official ClinicalTrials.gov record · National Institute of Neurological Disorders and Stroke (NINDS)

RecruitingNot a traditional drug phaseBerlin, State of Berlin
Not a traditional drug phase: testing Glucocorticoid treatment for Osteoporosis

Glucocorticoids remain to be among the most important and most frequently used anti-inflammatory and immunosuppressive or immune-modulatory acting drugs to treat rheumatic (and other) diseases. Unfortunately, glucocorticoids also exert undesired effects, especially if higher dosages have to be given over longer periods of time.

NCT02719314 · Official ClinicalTrials.gov record · Prof Dr Frank Buttgereit

RecruitingPhase 1Houston, Texas
Phase 1: testing Gemcitabine for Malignant Neoplasm of Bone and Articular Cartilage

Any time the words "you," "your," "I," or "me" appear, it is meant to apply to the potential participant. The goal of this clinical research study is to find the highest tolerable dose of gemcitabine that can be given by inhalation (breathing it as a mist) to patients with solid tumors that have spread to the lungs from other parts of the body.

NCT03093909 · Official ClinicalTrials.gov record · M.D. Anderson Cancer Center

RecruitingNot a traditional drug phaseSacramento, California
Not a traditional drug phase: VR Treatment for ADHD

Problems with distraction are widespread in the 21st century, but for people with developmental delays or behavioral challenges they can have more damaging effects. For example, susceptibility to distraction is associated with worse school and social performance, lower high school graduation rates, and increased incidence of serious accidents.

NCT03221244 · Official ClinicalTrials.gov record · University of California, Davis

RecruitingNot a traditional drug phaseSan Donato Milanese, Milan
Not a traditional drug phase: measurement of RNAs for Heart Failure

This study is aimed to investigate the global transcriptome in order to determine the expression profile of messenger RNAs (mRNAs), as well as long noncoding- (lncRNAs) and micro noncoding-RNAs (miRNAs) in heart failure (HF) and in aortic stenosis (AS). The aim is to clarify their role in cardiac disease pathogenesis, as well as their potential as biomarkers.

NCT03268135 · Official ClinicalTrials.gov record · IRCCS Policlinico S. Donato

RecruitingNot a traditional drug phaseMontreal, Quebec
Not a traditional drug phase: Acoustic radiation force impulse (ARFI), magnetic resonance elastography (MRE) for Nonalcoholic Fatty Liver Disease (NAFLD)

Nonalcoholic fatty liver disease is the most common liver disease in Western countries, due in large part to its association with type 2 diabetes and obesity. The more advanced form of this disease is known as nonalcoholic steatohepatitis (NASH).

NCT03572465 · Official ClinicalTrials.gov record · Centre hospitalier de l'Université de Montréal (CHUM)

RecruitingNot a traditional drug phaseLumezzane, Brescia
Not a traditional drug phase: Maximal strenght training (MST) plus endurance training (ET) for Chronic Obstructive Pulmonary Disease

In the context of pulmonary rehabilitation of COPD patients, recent guidelines and metanalysis describe that Resistance Training (RT) can be successfully performed alone or in conjunction with Endurance Training (ET) without evidence of side effects. Maximal Strength Training (MST) is a kind of RT typically performed at \~85-90% of 1RM with maximal velocity to be developed in the concentric phase.

NCT03799354 · Official ClinicalTrials.gov record · Istituti Clinici Scientifici Maugeri SpA

RecruitingNot a traditional drug phaseChicago, Illinois
Not a traditional drug phase: real iTBS for Mild Traumatic Brain Injury

This study will determine (i) the magnitude of immediate and sustained effects of a current clinical standard interactive computer attention processing training (APT) when combined with intermittent theta burst stimulation (iTBS), a type of repetitive transcranial magnetic stimulation and (ii) determine how APT + iTBS changes the neurocognitive system of attention in individuals with persistent attention deficits related to mTBI +/- PTSD.

NCT03819608 · Official ClinicalTrials.gov record · Northwestern University

RecruitingNot a traditional drug phaseNew York, New York
Not a traditional drug phase: Respiratory Mechanics for ARDS

This is a multicenter randomly assigned controlled clinical trial with an adaptive design assessing the how well it works of setting the ventilator based on measurements of respiratory mechanics (recruitability and effort) to reduce Day 60 mortality in patients with acute respiratory distress syndrome (ARDS). The CAVIARDS study is also a basket trial; a basket trial design examines a single intervention in multiple disease populations.

NCT03963622 · Official ClinicalTrials.gov record · Unity Health Toronto

RecruitingPhase 2 / Phase 3Birmingham, Alabama
Phase 2 / Phase 3: testing Temozolomide for Glioblastoma

Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and recurrent GBM. All institutions are enrolling Newly Diagnosed participants.

NCT03970447 · Official ClinicalTrials.gov record · Global Coalition for Adaptive Research

RecruitingPhase 1 / Phase 2Houston, Texas
Phase 1 / Phase 2: testing Ocrelizumab infusion for Schizo-Affective Type of Psychosis

Some people who have what doctors currently call schizophrenia or bipolar disease may actually have a brain disease caused by auto-antibodies. Auto-antibodies are produced when the normal defense mechanism of the body goes wrong and begins to attack the body, similar to "friendly fire." Auto-antibodies attack brain receptors and then the person who has this problem begins to have hallucinations and other manifestations of schizophrenia, like feeling that people can see what they are thinking and also feeling that other people do not like them.

NCT03971487 · Official ClinicalTrials.gov record · The Methodist Hospital Research Institute

RecruitingNot a traditional drug phaseBirmingham, Alabama
Not a traditional drug phase: Bilateral Salpingectomy for Ovarian Carcinoma

This clinical trial evaluates how well two surgical procedures (bilateral salpingectomy and bilateral salpingo-oophorectomy) work in reducing the risk of ovarian cancer for individuals with BRCA1 mutations. Bilateral salpingectomy involves the surgical removal of fallopian tubes, and bilateral salpingo-oophorectomy involves the surgical removal of both the fallopian tubes and ovaries.

NCT04251052 · Official ClinicalTrials.gov record · NRG Oncology

RecruitingPhase 1Lille
Phase 1: Surgery with Neoadjuvant stereotactic body radiation therapy for Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is the fifth more common cancer in the world, with high mortality rates, due to the low number of patients who are eligible for therapy with curative intent, like surgical resection. Moreover, surgical resection is associated with a high risk of tumor recurrence, because of the tumor seeding through microscopic intrahepatic vessels that surround the tumor, the so-called "microvascular invasion".

NCT04587739 · Official ClinicalTrials.gov record · University Hospital, Lille

RecruitingNot a traditional drug phaseRichmond, Virginia
Not a traditional drug phase: Antioxidant for Peripheral Vascular Diseases

The purpose of this research study is to examine the role oxidants, substances produced in the blood that can damage blood vessel function, may play in blood vessel function in healthy individuals as well as individuals with mental health disorders (posttraumatic stress disorder (PTSD) and/or generalized anxiety disorder (GAD)).

NCT04916327 · Official ClinicalTrials.gov record · Virginia Commonwealth University

RecruitingNot a traditional drug phaseMontreal, Quebec
Not a traditional drug phase: EUS-CPN without bupivacaine for Pancreatic Cancer

Endoscopic ultrasound (EUS) allows EUS-guided trans gastric injection of absolute alcohol around the base of the celiac plexus (celiac plexus neurolysis (EUS-CPN)), to help alleviate pain associated with pancreatic cancer. It is standard procedure to inject bupivacaine immediately before injecting absolute alcohol, to theoretically prevent pain that may occur during and after the procedure.

NCT04951804 · Official ClinicalTrials.gov record · Centre hospitalier de l'Université de Montréal (CHUM)

RecruitingNot a traditional drug phaseAurora, Colorado
Not a traditional drug phase: At Home Self-Collections for HIV Treatment

The goal of this watch-and-measure (no experimental treatment required) study is to establish an operational framework for home self-collections of blood samples to be used for antiviral drug concentration measurements. Participants will continue on their prescribed antiviral(s) for HIV treatment or prevention and followed for up to approximately 1 year.

NCT04979728 · Official ClinicalTrials.gov record · University of Colorado, Denver

RecruitingPhase 2Loma Linda, California
Phase 2: testing Obinutuzumab for Lupus Nephritis

This phase II, randomly assigned, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment study is designed to measure the safety, how well it works and pharmacokinetics (PK) of obinutuzumab in adolescent participants (AP) aged 12 to less than 18 with biopsy-confirmed proliferative lupus nephritis (LN). It will also evaluate open label safety and PK of obinutuzumab in pediatric participants (PP), aged 5 to \<12 with LN.

NCT05039619 · Official ClinicalTrials.gov record · Hoffmann-La Roche

RecruitingNot a traditional drug phaseLos Angeles, California
Not a traditional drug phase: Deep Brain Stimulation for Fear

Anxiety disorders such as post-traumatic stress disorder (PTSD) and generalized anxiety disorder (GAD) affect a large number of individuals with a significant portion of patients failing to improve with current treatments. this study wants to understand the brain mechanisms that produce fear and anxiety in humans.

NCT05120635 · Official ClinicalTrials.gov record · Duke University

RecruitingPhase 4Cleveland, Ohio
Phase 4: testing Ustekinumab for Psoriasis

The investigators propose to improve the possibility of reaching skin resolution by identifying certain markers or gene patterns that may predict patient response to certain psoriasis drugs ahead of time, thus eliminating or reducing the trial-and-error approach often employed. The ability to rule out (or in) specific therapeutics based on predictive how well it works would lead to a more personalized approach for psoriasis treatment.

NCT05270733 · Official ClinicalTrials.gov record · University Hospitals Cleveland Medical Center

RecruitingNot a traditional drug phaseNashville, Tennessee
Not a traditional drug phase: none, observational study for Aging

The primary objective of the Vanderbilt Alzheimer's Disease Research Center (VADRC) is to provide local and national researchers with access to a well-characterized and diverse clinical cohort, including participant referrals, biosamples, clinical data, and neuroimaging data. The VADRC Clinical Core will create an infrastructure to support research efforts of both local and national investigator studies to develop early detection, prevention, and treatment strategies for Alzheimer's disease.

NCT05372172 · Official ClinicalTrials.gov record · Vanderbilt University Medical Center

RecruitingPhase 2Birmingham, Alabama
Phase 2: testing Docetaxel for Metastatic Salivary Gland Carcinoma

This phase II trial compares the effect of usual treatment of docetaxel chemotherapy plus trastuzumab, to ado-emtansine (T-DM1) in patients with HER2-positive salivary gland cancer that has come back (recurrent), that has spread from where it first started (primary site) to other places in the body, or cannot be removed by surgery (unresectable). This trial is also testing how well trastuzumab deruxtecan works in treating patients with HER2-low recurrent or metastatic salivary gland cancer.

NCT05408845 · Official ClinicalTrials.gov record · NRG Oncology

RecruitingPhase 1 / Phase 2Bethesda, Maryland
Phase 1 / Phase 2: testing RIC for HIV

Background: People living with HIV(PLWH) are at a higher risk for cancers that may be curable with a bone marrow transplant. HIV infection itself is no longer a reason to not get a transplant, for patients who otherwise have a standard reason to need transplant.

NCT05470491 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)

RecruitingNot a traditional drug phaseEdmonton, Alberta
Not a traditional drug phase: Supporting Patients by Family Education in Psychotic Illness Group for Psychotic Disorders

Background: A lack of education, resources, and support for family carers of young adults with psychotic illnesses leaves them ill-equipped to support their loved one. Although family support groups exist, few groups offer evidence-based, skills-focused, psychoeducation taught by certified professionals and provided on a public-health level.

NCT05500001 · Official ClinicalTrials.gov record · University of Alberta

RecruitingPhase 2Birmingham, Alabama
Phase 2: testing Azacitidine for Acute Myeloid Leukemia

This phase II MyeloMATCH treatment trial tests whether the standard approach of cytarabine and daunorubicin in comparison to the following experimental regimens works to shrink cancer in patients with high risk acute myeloid leukemia (AML): 1) daunorubicin and cytarabine liposome alone; 2) cytarabine and daunorubicin with venetoclax; 3) azacitidine and venetoclax; 4) daunorubicin and cytarabine liposome and venetoclax. "High-risk" refers to traits that have been known to make the AML harder to treat.

NCT05554406 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)

RecruitingPhase 4New York, New York
Phase 4: testing Herpes Zoster Subunit (HZ/su) Vaccine for Systemic Lupus Erythematosus

This randomly assigned, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment, non-inferiority crossover study will measure the Herpes Zoster Sunbit (HZ/su) vaccine in SLE patients in order to evaluate safety and immunogenicity in patients with variable baseline clinical activities, ages and immunosuppressant exposures. The investigators hypothesize that HZ/su administration will be non-inferior to dummy treatment (placebo) with respect to the risk of moderate or severe SLE flare(s) occurring within 24 weeks of receiving the first dose of the assigned treatment.

NCT05559671 · Official ClinicalTrials.gov record · NYU Langone Health

RecruitingPhase 2Birmingham, Alabama
Phase 2: testing Alpelisib for Advanced Malignant Solid Neoplasm

This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally advanced) or have spread to other places in the body (advanced) and have progressed on at least one line of standard systemic therapy or have no standard treatment that has been shown to prolong overall survival may be candidates for these trials.

NCT05564377 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)

RecruitingNot a traditional drug phaseBeijing
Not a traditional drug phase: Level III portable sleep study for Sleep Apnea

The investigators propose a prospective, watch-and-measure (no experimental treatment required) study to determine the impact of OSA and associated physiological parameters on clinical outcomes in patients with pulmonary hypertension. The prevalence, phenotypes, and predictors of OSA in the setting of pulmonary hypertension will also be investigated.

NCT05595200 · Official ClinicalTrials.gov record · Chinese Pulmonary Vascular Disease Research Group

RecruitingNot a traditional drug phaseMarseille
Not a traditional drug phase: Psychological assessments for Amyotrophic Lateral Sclerosis

Amyotrophic lateral sclerosis (ALS) is a degenerative neurological disease that causes progressive motor disability and is life threatening within a few years. The severity of the disease, the progressive loss of autonomy that leads to dependence on family and caregivers, and the lack of effective treatment sometimes leads patients to a loss of hope and to dark thoughts.

NCT05632757 · Official ClinicalTrials.gov record · Assistance Publique Hopitaux De Marseille

RecruitingNot a traditional drug phaseWashington D.C., District of Columbia
Not a traditional drug phase: Questionnaires for Non-Muscle Invasive Bladder Cancer

This study wants to evaluate mood changes in patients with Non-Muscle Invasive Bladder Cancer who are receiving intravesical Bacillus Calmete-Guerin (BCG). Patients with Non-Muscle Invasive Bladder Cancer receiving intravesical treatments are eligible to participate in this study.

NCT05672615 · Official ClinicalTrials.gov record · Johns Hopkins University

RecruitingPhase 3Birmingham, Alabama
Phase 3: testing Bleomycin Sulfate for Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8

This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in improving survival in patients with stage I and II classical Hodgkin lymphoma. Brentuximab vedotin is in a class of medications called antibody-drug conjugates.

NCT05675410 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)

RecruitingPhase 3Los Angeles, California
Phase 3: testing Linvoseltamab for Relapsed Refractory Multiple Myeloma (RRMM)

This study is researching an experimental drug called linvoseltamab, also called REGN5458. Linvoseltamab has previously been studied by itself (without other cancer drugs) in participants who had advanced multiple myeloma that returned and needed to be treated again after many other therapies had failed.

NCT05730036 · Official ClinicalTrials.gov record · Regeneron Pharmaceuticals

RecruitingNot a traditional drug phaseDetroit, Michigan
Not a traditional drug phase: HEART Camp for HFpEF - Heart Failure With Preserved Ejection Fraction

The goal of this study is to learn more about patients with heart failure with preserved ejection fraction (HFpEF) and exercise. Investigators want to see if meeting with a coach in person or by video conference will help these patients exercise, feel better, and change markers in their blood.

NCT05784753 · Official ClinicalTrials.gov record · University of Nebraska

RecruitingPhase 2Duarte, California
Phase 2: Biospecimen Collection for Lung Non-Small Cell Carcinoma

This phase II trial tests the safety of positron emission tomography (PET) guided stereotactic body radiation therapy (SBRT) and how well it works to treat non-small cell lung cancer (NSCLC), melanoma, and renal cell carcinoma (RCC) that has up to 5 sites of progression (oligoprogression) compared to standard SBRT. SBRT uses special equipment to position a patient and deliver radiation to tumors with high precision.

NCT05830058 · Official ClinicalTrials.gov record · City of Hope Medical Center

RecruitingPhase 2Milan, Lombardia/MI
Phase 2: testing Trastuzumab deruxtecan for Colorectal Cancer

This is a window-of-opportunity umbrella platform trial enrolling non-metastatic resectable colorectal patients selected for the presence of a specific targetable molecular alteration. The study aims to test the activity of specific targeted agents/combinations given as a short-course pre-operative strategy, matched with the specific alteration detected, followed by standard of care surgery.

NCT05845450 · Official ClinicalTrials.gov record · Gruppo Oncologico del Nord-Ovest

RecruitingNot a traditional drug phaseSaint-Denis
Not a traditional drug phase: Cardiac coherence for Long COVID

Despite the controversy, on October 6, 2021, the World Health Organization (WHO) recognized Long Coronavirus disease (COVID) by officially defining it: " symptoms appeared 3 months after the onset of the primary infection by the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), persisting for at least 2 months and which cannot be explained by any other condition ". Long COVID can affects any type of patient and has polymorphic and fluctuating symptoms over time.

NCT05851859 · Official ClinicalTrials.gov record · Centre Hospitalier Universitaire de la Réunion

RecruitingNot a traditional drug phaseToulouse
Blocking TNF to Potentiate the ICI-dependent Immune Awakening in Melanoma

Cutaneous melanoma is a bad prognosis skin cancer, which can be treated with immune checkpoint inhibitors (ICI), such as anti-PD-1 (nivolumab, nivo) and anti-CTLA-4 (ipilimumab, ipi). However, about 50% of patients do not respond or relapse within 3 years post therapy induction, and immune-related side effects (irAEs), such as colitis, are triggered and can be treated with TNF inhibitor (TNFi; ie, infliximab, inflix).

NCT05867004 · Official ClinicalTrials.gov record · Institut Claudius Regaud

RecruitingPhase 4Aalborg
Phase 4: testing Lithium for Depression, Bipolar

The goal is to study the effect of lithium compared to cariprazine in patients with depression in a bipolar disease. The main question it aims to answer is: Difference in change between the two groups from baseline to after 8 weeks treatment on Hamilton Ratings Scale for Depression, 6-item version (HDS-6) you would be randomly assigned to treatment with either lithium or cariprazin.

NCT05913947 · Official ClinicalTrials.gov record · Aalborg University Hospital

RecruitingPhase 1New Haven, Connecticut
Phase 1: testing Ketamine for Depressive Disorder, Major

The proposed study will assess the combined effect of perampanel and ketamine on the anti-depressant response in individuals with treatment resistant depression. this study wants to test the hypothesis that stimulation of Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid receptors (AMPAR) is critical to the anti-depressant response of ketamine.

NCT05915013 · Official ClinicalTrials.gov record · Yale University

RecruitingPhase 4Irvine, California
Phase 4: testing Randomization to either Amphetamine (AMP) class of stimulant medication or Methylphenidate (MPH) class of stimulant medication for ADHD

This study is a pragmatic clinical trial examining the comparative effectiveness of two stimulant medications (methylphenidate and amphetamine) in the treatment of ADHD in children and adolescents with autism. Using a sequential, multiple assignment randomization trial (SMART) design the study will not only assess these two medications but also the role of an increasingly popular class of ADHD medication, the alpha-2 agonists.

NCT05916339 · Official ClinicalTrials.gov record · Daniel Coury

RecruitingPhase 3Heidelberg, Baden-Württenberg
Phase 3: testing Dapagliflozin for Chronic Kidney Failure in Children and Young Adults

Recent trials have demonstrated positive renal outcomes of sodium-glucose co-transporter-2 inhibitors (SGLT2i) additive to angiotensin-converting-enzyme inhibitors (ACEis) in adult patients with diabetic and non-diabetic chronic kidney disease (CKD). The hypothesis of DOUBLE PRO-TECT Alport is to demonstrate superiority of the SGLT2i dapagliflozin in preventing progression of the chronic kidney disease Alport syndrome in children and young adults at early stages of disease.

NCT05944016 · Official ClinicalTrials.gov record · University Hospital Goettingen

RecruitingNot a traditional drug phaseMontpellier
Not a traditional drug phase: Magnetic Resonance Imaging for Multiple Sclerosis

Several prospective monocentric cohorts of between 250 and 1000 patients have been set up in order to characterize more precisely the evolution of the disease. Nevertheless, due to an initial recruitment carried out in the years 2000-2010, they do not constitute a faithful representation of the patients followed in clinical routine, in particular in terms of distribution of treatments.

NCT05962177 · Official ClinicalTrials.gov record · University Hospital, Montpellier

RecruitingPhase 2Jacksonville, Florida
Phase 2: Clinical Encounter for Advanced Anal Carcinoma

This clinical trial studies the effect of cancer directed therapy given at-home versus in the clinic for patients with cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Currently most drug-related cancer care is conducted in infusion centers or specialty hospitals, where patients spend many hours a day isolated from family, friends, and familiar surroundings.

NCT05969860 · Official ClinicalTrials.gov record · Mayo Clinic

RecruitingNot a traditional drug phaseNew York, New York
Not a traditional drug phase: Transcutaneous electrical nerve stimulation unit (TENS) for Chronic Kidney Disease

The purpose of this pilot treatment study is to collect preliminary data on the application of a transcutaneous auricular vagal nerve stimulation (taVNS) device in patients with chronic kidney disease (CKD). This data will enhance understanding of the short-term safety, tolerability and effects of this novel therapeutic approach in the setting of CKD.

NCT05981183 · Official ClinicalTrials.gov record · NYU Langone Health

RecruitingPhase 2Duarte, California
Phase 2: testing Osimertinib for Lung Non-Small Cell Carcinoma

This phase II trial tests how well biologically guided radiation therapy (BgRT) and stereotactic body radiation therapy (SBRT) with osimertinib works for the treatment of EGFR positive non-small cell lung carcinoma that has spread from where it first started (primary site) to a limited number of anatomic sites (oligoprogressive). BgRT is radiation that uses specialized imaging to during treatment to target the active tumor and direct radiation to tumors in order to kill and shrink tumor cells.

NCT06014827 · Official ClinicalTrials.gov record · City of Hope Medical Center

RecruitingPhase 3Birmingham, Alabama
Phase 3: testing Cyclophosphamide for Anatomic Stage II Breast Cancer AJCC v8

This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

NCT06058377 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)

RecruitingNot a traditional drug phaseBordeaux
Not a traditional drug phase: RNA sequencing for Amyotrophic Lateral Sclerosis

Genetic diagnosis of Amyotrophic Lateral Sclerosis (ALS) could identify the origin of the disease, potentially allowing the patient to pursue targeted/gene therapy. However, many familial forms of ALS are genetically undiagnosed, either because no variant has been detected in the genes of interest, or because the detected variant(s) have uncertain significance.

NCT06083584 · Official ClinicalTrials.gov record · Centre Hospitalier Universitaire de Nīmes

RecruitingPhase 2 / Phase 3Sydney, Australia
Phase 2 / Phase 3: testing Acetyl-l-carnitine for Amyotrophic Lateral Sclerosis

Phase II/III multicenter, randomly assigned, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment trial on acetyl-L-carnitine (ALCAR) in subjects living with amyotrophic lateral sclerosis (ALS). Primary study aim: The clinical objective consists of assessing the how well it works of ALCAR (two different dosages will be tested: 1.5g/day and 3g/day) on the progression of functional disability (loss of self-sufficiency), as measured by the ALSFRS-R scale.

NCT06126315 · Official ClinicalTrials.gov record · Mario Negri Institute for Pharmacological Research

RecruitingPhase 4Columbia, Missouri
Phase 4: testing GLP-1 receptor agonist for Morbid Obesity

Glucagon-like peptide 1 (GLP-1) is a hormone that helps regulate blood glucose levels through improved insulin sensitivity and release of insulin from the pancreas, control hunger, induce satiety and plays a role in the metabolic health of a person. GLP-1 receptor agonists (GLP1-RAs) have been shown to be effective in achieving weight loss in patients with type 2 diabetes while improving blood glucose control.

NCT06132477 · Official ClinicalTrials.gov record · University of Missouri-Columbia

RecruitingPhase 3Boston, Massachusetts
Phase 3: testing Dalfampridine 10 MG [Ampyra] for Multiple Sclerosis

The goal of this clinical trial is to evaluate if combining a medication that can help improve walking in people with multiple sclerosis (MS) with a physical therapy program is better for improving walking than either treatment alone. The main questions this study will answer are: * Does combining dalfampridine with physical therapy improve mobility more than physical therapy without concurrent dalfampridine?

NCT06136728 · Official ClinicalTrials.gov record · MGH Institute of Health Professions

RecruitingPhase 1Aurora, Colorado
Phase 1: testing TTI-101 for Pancreatic Cancer

The survival rate for patients with pancreatic cancer remains at a dismal 10% or less at 5 years, and although trials integrating stereotactic body radiation therapy (SBRT) alone have shown improvement in local control, initial invigoration of immune response, and relief of symptom burden, SBRT has not demonstrated any improvement in survival. Preclinical research has established that STAT3 inhibition given concurrently with SBRT and in the maintenance phase acts as a synergistic agent that enhances the pro-inflammatory effects of SBRT while reducing its undesired effects (including fibrosis and immunosuppression).

NCT06141031 · Official ClinicalTrials.gov record · Washington University School of Medicine

RecruitingPhase 1 / Phase 2Bethesda, Maryland
Phase 1 / Phase 2: testing PLX038 for Glioma

Background: About 90,000 new cases of brain and spinal cord tumors are diagnosed annually in the United States. Most of these tumors are benign; however, about 30% are malignant, and 35% of people with malignant tumors in the brain and spinal cord will die within 5 years.

NCT06161519 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)

RecruitingNot a traditional drug phaseBologna
Not a traditional drug phase: testing Dupilumab for Atopic Dermatitis

In adolescents treated with dupilumab, clinical trials showed significant improvement of atopic dermatitis (AD) signs and symptoms, with a good safety profile. In these clinical trials, only patients with Eczema Area and Severity Index (EASI) score greater than or equal to (≥) 16 were enrolled, and effectiveness on sensitive/visible areas was not specifically evaluated.

NCT06192563 · Official ClinicalTrials.gov record · Sanofi

RecruitingPhase 3Birmingham, Alabama
Phase 3: testing Pembrolizumab for Metastatic Non-small Cell Lung Cancer

This study, known as LUNAR-2, aims to investigate the effectiveness and safety of using TTFields, delivered by the NovoTTF-200T device, concomitantly administered with pembrolizumab and platinum-based chemotherapy for patients with advanced non-small cell lung cancer that has spread to other parts of the body. The primary goals of the study are to assess overall survival and progression-free survival.

NCT06216301 · Official ClinicalTrials.gov record · NovoCure GmbH

RecruitingPhase 2Ottawa, Ontario
Phase 2: testing Darifenacin 7.5 MG Extended Release Oral Tablet for Amyotrophic Lateral Sclerosis

Amyotrophic lateral sclerosis (ALS) is a progressive neurological disorder characterized by selective death of upper and lower motor neurons, which leads to severe disability and fatal outcomes. One of the major hallmarks of ALS is the denervation of neuromuscular junctions (NMJs), which is one of the earliest events seen in ALS patients and mouse models of ALS.

NCT06249867 · Official ClinicalTrials.gov record · Oliver Blanchard

RecruitingPhase 2Duarte, California
Phase 2: testing F-18 16 Alpha-Fluoroestradiol for Anatomic Stage IV Breast Cancer AJCC v8

This phase II trial tests how well stereotactic body radiation therapy (SBRT) works in treating patients with estrogen receptor positive (ER +) breast cancer that has spread from where it first started to other places in the body (metastatic) and has limited disease progression (oligoprogression). Currently, the standard of care for breast cancer patients with oligoprogressive disease is to change systemic therapy when progression occurs.

NCT06260033 · Official ClinicalTrials.gov record · City of Hope Medical Center

RecruitingNot a traditional drug phaseEl Paso, Texas
Not a traditional drug phase: Parenting-STAIR Modular (PSTAIR-M) for PTSD

The goal of this study is to assess Parenting STAIR Modular (PSTAIR-M), a promising and innovative intervention for military-connected mothers (MCM) who have experienced trauma and their young children (ages 2-10). PSTAIR-M aims to help mothers manage the strong feelings that sometimes happen after experiencing something scary or stressful, as well as to better connect with their children and manage their behavior effectively.

NCT06262178 · Official ClinicalTrials.gov record · New York University

RecruitingNot a traditional drug phaseMany Locations, New Jersey
Not a traditional drug phase: testing Finerenone (BAY 94-8862) for Chronic Kidney Disease

This is an watch-and-measure (no experimental treatment required) study, in which data from people in Asia and in the United States with chronic kidney disease (CKD) together with type 2 diabetes (T2D) are studied. The participants in this study are already receiving the study treatment finerenone as part of their regular care from their doctors.

NCT06278207 · Official ClinicalTrials.gov record · Bayer

RecruitingNot a traditional drug phaseWoluwe-Saint-Lambert
Not a traditional drug phase: electroencephalography, electrocardiogram, pupillometry, evoked potentials, light administration for Refractory Epilepsy

Vagus nerve stimulation (VNS) is an added on top of your current treatment treatment for refractory epilepsy. Although widely used, there is still a substantial number of patients with insufficient response.

NCT06304389 · Official ClinicalTrials.gov record · Cliniques universitaires Saint-Luc- Université Catholique de Louvain

RecruitingNot a traditional drug phaseLondon
Not a traditional drug phase: testing Semaglutide Oral Product for Steroid-Induced Diabetes

TITLE: How GLP-1 Analogues prevent steroid-induced diabetes (The GAPSID Study) DESIGN: A neither you nor the study doctors know who gets the real treatment study evaluating how GLP-1 analogues, compared with metformin, prevent hyperglycaemia in response to a 7-day course of dexamethasone (DEX) 6 mg once daily. This is a mechanistic experimental medicine study.

NCT06318442 · Official ClinicalTrials.gov record · Imperial College London

RecruitingNot a traditional drug phaseCharleston, South Carolina
Not a traditional drug phase: Trauma Focused Cognitive Behavioral Therapy for Post-Traumatic Stress Disorder

The current study will evaluate TF-CBT delivered via tele-health for youth presenting with trauma symptoms via a randomly assigned controlled trial. Goals of the current study are to examine the effectiveness of Tele-TF-CBT delivered by community providers in Puerto Rico in improving youth trauma outcomes.

NCT06332209 · Official ClinicalTrials.gov record · Medical University of South Carolina

RecruitingPhase 3Los Angeles, California
Phase 3: testing BNT323/DB-1303 for Endometrial Cancer

The study is divided into two cohorts (Cohort 1 and Cohort 2), to which you would be enrolled based on the amount of human epidermal growth factor receptor 2 (HER2) in their tumor sample. In Cohort 1, the main goal is to assess how well BNT323 (also known as DB-1303) or chemotherapy (doxorubicin or paclitaxel \[or docetaxel, if participants cannot take paclitaxel\]) works by determining the progression-free survival (PFS) of participants who have been previously treated with immune checkpoint inhibitors (ICIs).

NCT06340568 · Official ClinicalTrials.gov record · BioNTech SE

RecruitingPhase 2Boston, Massachusetts
Phase 2: testing Pyridostigmine for ME/CFS

The LIFT will be conducted at Brigham and Women's Hospital (BWH) of Harvard Medical School, focusing on the effect of Pyridostigmine (Mestinon) and Low-Dose Naltrexone (LDN) in subjects aged 18-70 meeting the Canadian consensus criteria (CCC) for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) as well as having specifically Orthostatic Intolerance (OI). Long COVID (LC) subjects will also be included if they meet CCC and have OI.

NCT06366724 · Official ClinicalTrials.gov record · Brigham and Women's Hospital

RecruitingNot a traditional drug phaseMobile, Alabama
Not a traditional drug phase: CBT+ Health coach for Pain

The study, known as the Peer suppoRt for adolescents and Emerging adults with Sickle cell pain: promoting ENgagement in Cognitive behavioral thErapy (PRESENCE), aims to determine the effectiveness of digital CBT in reducing pain, opioid use, and healthcare utilization among AYAs with SCD. It also seeks to understand the role of personalized peer support in enhancing engagement and outcomes of digital CBT interventions.

NCT06374238 · Official ClinicalTrials.gov record · University of Pittsburgh

RecruitingNot a traditional drug phaseManhasset, New York
Not a traditional drug phase: Electroencephalography (EEG) signals, which will be detected noninvasively from dry scalp surface electrodes while the subjects are in a state of wakeful rest. for Systemic Lupus Erythematosus

Patients with systemic lupus erythematosus (SLE) often experience a frustrating decline of their cognitive skills that includes considerable problems in attention, learning, and memory. This lupus-related cognitive dysfunction (termed SLE-CD) is recognized as the most prevalent of the nineteen neuropsychiatric SLE syndromes, as it affects up to 80% of patients and can significantly decrease their quality of life.

NCT06378736 · Official ClinicalTrials.gov record · Northwell Health

RecruitingEarly phase 1Chicago, Illinois
Early phase 1: testing Empagliflozin 10 MG for Chronic Kidney Diseases

The goal of this study is to learn if a clinical trial of sodium-glucose co-transporter 2 inhibitors (SGLT2i) is possible in youth with chronic kidney disease (CKD). The investigators also plan to explore whether treatment with SGLT2i (Empagliflozin) helps improve risk factors for worsening kidney and heart disease.

NCT06430684 · Official ClinicalTrials.gov record · Ann & Robert H Lurie Children's Hospital of Chicago

RecruitingPhase 1New Haven, Connecticut
Phase 1: testing Psilocybin for Transdiagnostic

The primary objective of this study is to investigate the safety, feasibility, and tolerability of psilocybin treatment in individuals with functional impairment due to psychiatric symptoms. The secondary objective of this study is to determine whether individuals with functional impairments due to psychiatric symptoms will experience statistically significant symptom reduction and functional improvement from baseline symptom measurements (Visit 3) to 1-week (Visit 7), 4-weeks (Visit 8), and 6-weeks (Visit 9) post dosing.

NCT06442423 · Official ClinicalTrials.gov record · Yale University

RecruitingNot a traditional drug phaseMontreal, Quebec
Not a traditional drug phase: Implementation of elleFA smartphone application for Endometriosis

Endometriosis is a chronic incurable disease where endometrial-like tissue grows outside of the uterus, and causes symptoms such as debilitating menstrual pain, pain during intercourse, infertility, constipation, and bloating, which hurts their quality of life. Endometriosis is estimated to affect approximately 10% of women.

NCT06452407 · Official ClinicalTrials.gov record · McGill University Health Centre/Research Institute of the McGill University Health Centre

RecruitingNot a traditional drug phaseMobile, Alabama
Not a traditional drug phase: HistoSonics Edison System for Liver Neoplasms

The goal of this watch-and-measure (no experimental treatment required) study is to collect information on the use of the HistoSonics Edison System for the treatment of liver tumors. The main aim is to understand how different patient characteristics and procedural characteristics may affect histotripsy success at 36 hours post-histotripsy procedure.

NCT06486454 · Official ClinicalTrials.gov record · HistoSonics, Inc.

RecruitingNot a traditional drug phaseCambridge, Cambridgeshire
Not a traditional drug phase: testing R848 for Innate Immunity

Respiratory viral infections can be a cause of significant illness, particularly in vulnerable individuals as seen in the COVID-19 pandemic. An underactive or overactive immune response can lead to ineffective resolution of inflammation after an infection, especially in people with airway diseases such as asthma.

NCT06488118 · Official ClinicalTrials.gov record · Akhilesh Jha

RecruitingNot a traditional drug phaseBethesda, Maryland
National Ophthalmic Genotyping and Phenotyping Network (eyeGENE (Registered Trademark)), Stage 3 - Expansio…

Background: The eyeGENE (Registered Trademark) program is a research resource for inherited eye conditions which includes genotypic and phenotypic data, imaging, and a corresponding biobank of DNA samples from people with a variety of eye diseases. Since 2007 this registry has been helping researchers learn more about the genetic sources for many inherited eye diseases.

NCT06491615 · Official ClinicalTrials.gov record · National Eye Institute (NEI)

RecruitingPhase 2Bethesda, Maryland
Phase 2: testing [18F]FAPI-74 for Sarcoma

Background: Fibroblast-activation protein (FAP) is an enzyme that appears in high numbers in cancer-associated fibroblasts of certain cancer types. \[18F\]FAPI-74 is a new PET (positron emission tomography) tracer, a substance that is injected into a person s body before an imaging scan.

NCT06503146 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)

RecruitingPhase 2Toronto, Ontario
Phase 2: testing Psilocybin 25 mg for Treatment Resistant Depression

Psilocybin, the chemical component of "magic mushrooms", has been administered with psychotherapy in several randomly assigned clinical trials (RCTs) showing large and sustained antidepressant effects. In healthy volunteers, the psychedelic effects of psilocybin have been shown to be blocked by administration of certain medications such as risperidone.

NCT06512220 · Official ClinicalTrials.gov record · Centre for Addiction and Mental Health

RecruitingNot a traditional drug phaseWashington D.C., District of Columbia
Not a traditional drug phase: Integrated Infectious Diseases and Substance Use Disorder Clinic (IC) for Opioid Use Disorder

This is a two-group randomly assigned controlled trial conducted at five hospitals across the U.S. designed to test the effectiveness of an Integrated infectious diseases/Substance Use Disorder outpatient clinic (IC) compared to treatment as usual aimed at reducing infection related readmissions and improving health outcomes in people hospitalized with an infection related to injecting opioids or stimulants.

NCT06513156 · Official ClinicalTrials.gov record · Elana Rosenthal

RecruitingPhase 2Toronto, Ontario
Phase 2: testing Psilocybin 25 mg for Treatment Resistant Depression

Psilocybin, the chemical component of "magic mushrooms", has been administered with psychotherapy in several randomly assigned clinical trials (RCTs) showing large and sustained antidepressant effects. this study wants to assess the feasibility, tolerability, and preliminary how well it works of psilocybin therapy for adults with chronic neuropathic pain and co-morbid treatment resistant depression.

NCT06518720 · Official ClinicalTrials.gov record · Centre for Addiction and Mental Health

RecruitingNot a traditional drug phaseBirmingham, Alabama
ASSESS ALL ALS Study

The ALL ALS Clinical Research Consortium is establishing research to collect a wide range of samples, clinical information and measurements from Amyotrophic Lateral Sclerosis (ALS) symptomatic, ALS gene carriers and control cohorts. This consortium is being funded by the National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH/NINDS) and managed by two clinical coordinating centers (CCC) at Barrow Neurological Institute and Massachusetts General Hospital.

NCT06578195 · Official ClinicalTrials.gov record · St. Joseph's Hospital and Medical Center, Phoenix

RecruitingPhase 4Birmingham, Alabama
Phase 4: testing Vedolizumab IV for Ulcerative Colitis

Ulcerative Colitis (UC) and Crohn's Disease (CD) are long-term conditions in the gut that can cause diarrhea, swelling (inflammation), bleeding from the anus, and belly pain. The main aim of this study is to check for how many participants with UC and CD signs and symptoms disappear after 3.5 months (14 weeks) of treatment with Vedolizumab (this is called remission).

NCT06581328 · Official ClinicalTrials.gov record · Takeda

RecruitingPhase 2Montreal, Quebec
Phase 2: testing Inactivated influenza vaccine (IIV) at baseline for COVID 19

The goal of this pragmatic embedded open-label, 2 x 2 factorial phase II randomly assigned controlled trial is to evaluate strategies to improve COVID-19 booster and influenza vaccine immunogenicity in people living with immunocompromising conditions (PLIC). The main questions it aims to answer are: 1.

NCT06599658 · Official ClinicalTrials.gov record · McGill University Health Centre/Research Institute of the McGill University Health Centre

RecruitingNot a traditional drug phaseGainesville, Florida
Not a traditional drug phase: EMPHASYS Cup with VHN for Osteoarthritis

The purpose of this research is to gather clinical and radiographic (X-ray) information about EMPHASYS™ acetabular shell (also called a hip 'cup') placement in total hip replacement surgery using a non-invasive surgical navigation system called VELYS™ hip navigation system with CUPTIMIZE™ Advanced Hip-Spine Analysis software. Data collected in this study will be compared with data collected from implantations using different cup positioning instrumentation and techniques to assess performance.

NCT06631638 · Official ClinicalTrials.gov record · DePuy Orthopaedics

RecruitingPhase 3Birmingham, Alabama
Phase 3: Survodutide for Metabolic Dysfunction Associated Steatohepatitis (MASH)

This study is open to adults who are at least 18 years old living with obesity and have: * a confirmed liver disease called non-alcoholic steatohepatitis (NASH)/metabolic associated steatohepatitis (MASH) and * moderate or advanced liver fibrosis People with a history of acute or chronic liver diseases other than MASH or chronic alcohol intake cannot take part in this study. this study wants to find out whether a medicine called survodutide helps people with MASH and moderate or advanced liver fibrosis improve their liver function.

NCT06632444 · Official ClinicalTrials.gov record · Boehringer Ingelheim

RecruitingPhase 3Peoria, Arizona
Phase 3: Survodutide for Metabolic Dysfunction Associated Steatohepatitis

This study is open to adults who are at least 18 years old and have: * A confirmed liver disease called non-alcoholic steatohepatitis (NASH) or * A confirmed liver disease called metabolic-associated steatohepatitis (MASH) * body-mass index (BMI) of 27 kg/m2 or more or * 25 kg/m2 or more if the participant is Asian. People with a history of other chronic liver diseases or high alcohol intake cannot take part in this study.

NCT06632457 · Official ClinicalTrials.gov record · Boehringer Ingelheim

RecruitingPhase 2Birmingham, Alabama
Phase 2: testing Cyclobenzaprine HCl for Acute Stress Reaction

This study will examine the safety and how well it works of TNX-102 SL to reduce ASR symptoms and behavioral changes among patients presenting to the emergency department (ED) after motor vehicle collision (MVC). Specifically, the investigators will perform the Optimizing Acute Stress reaction Interventions with TNX-102 SL (OASIS) Trial, a neither you nor the study doctors know who gets the real treatment compared with a dummy treatment randomly assigned clinical trial (RCT) to determine if TNX-102 SL initiated in the ED in the hours after MVC to high risk individuals, treats/reduces acute stress reaction (ASR)/acute stress disorder (ASD) symptoms (primary outcome), improves neurocognitive function, and prevents/reduces posttraumatic stress (PTS) symptoms (secondary outcomes) long term.

NCT06636786 · Official ClinicalTrials.gov record · University of North Carolina, Chapel Hill

RecruitingPhase 2Boston, Massachusetts
Phase 2: testing Semaglutide for Opioid Use Disorder

The is a pilot, 12-week, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment, randomly assigned trial of individuals with opioid use disorder (OUD) newly initiating buprenorphine to receive either weekly injections of semaglutide (n=23) or matching dummy treatment (placebo) (n=23). The primary aim is to determine the effects of semaglutide on cue-reactivity among individuals with OUD.

NCT06639464 · Official ClinicalTrials.gov record · Brigham and Women's Hospital

RecruitingPhase 2Tucson, Arizona
Phase 2: testing Ibrutinib for High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements

This phase II trial tests how well venetoclax, ibrutinib, prednisone, obinutuzumab, and Revlimid® (ViPOR) works in treating patients with CD10 negative diffuse large B-cell lymphoma (DLBCL) and high-grade lymphoma with MYC and BCL2 rearrangements that has come back after a period of improvement (relapsed) and/or that has not responded to previous treatment (refractory). Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors.

NCT06649812 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)

RecruitingNot a traditional drug phaseTours, France
Not a traditional drug phase: Basal tear collection for the analysis of metabo-lipidomic profiles and concentrations of protein biomarkers (Tau, phosphorylated Tau, Aβ 1-40, and Aβ 1-42) for Alzheimer Disease

The diagnosis of Alzheimer's disease (AD) relies on the detection of protein biomarkers, particularly in cerebrospinal fluid (e.g., Aβ and phosphorylated Tau) or through brain imaging. The invasive nature of lumbar puncture and the numerous contraindications have driven the search for early and reliable diagnostic biomarkers for AD.

NCT06661564 · Official ClinicalTrials.gov record · University Hospital, Tours

RecruitingPhase 3Phoenix, Arizona
Phase 3: testing Pembrolizumab for Clear Cell Renal Cell Carcinoma

This phase III trial compares the effect of adding tivozanib to standard therapy pembrolizumab versus pembrolizumab alone for the treatment of patients with high-risk renal cell carcinoma (RCC). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

NCT06661720 · Official ClinicalTrials.gov record · Alliance for Clinical Trials in Oncology

RecruitingPhase 4Hong Kong
Phase 4: testing SGLT2 inhibitor (Dapagliflozin 10mg) for Congenital Heart Disease

Repaired Tetralogy of Fallot (rTOF) is the leading cause of congenital cyanotic heart disease worldwide, involving up to 7-10% of congenital heart disease. With advances in open-heart surgical repair techniques and medical therapies, there is a significant increase in patients with rTOF surviving till late adulthood.

NCT06668389 · Official ClinicalTrials.gov record · The University of Hong Kong

RecruitingNot a traditional drug phaseHouston, Texas
Not a traditional drug phase: E-trigger for NAFLD

Non-alcoholic fatty liver disease (NAFLD) is a new condition that has become the most common chronic liver disease in the world and a main cause of liver cirrhosis, liver failure and liver cancer. Obesity and diabetes, conditions that are very common among Veterans are the main risk factors for NAFLD.

NCT06671886 · Official ClinicalTrials.gov record · VA Office of Research and Development

RecruitingNot a traditional drug phaseKristianstad, Skåne County
Not a traditional drug phase: The Cognitive Orientation to Daily Occupational Performance Approach for Intellectual Disability, Mild

Intellectual disability (ID) affects a person throughout life and includes difficulties to manage what is expected in everyday life based on age. One difficulty is to create strategies for and solve problems related to everyday occupations.

NCT06691698 · Official ClinicalTrials.gov record · Örebro University, Sweden

RecruitingPhase 3Cairo, Al Abbasia
Phase 3: testing Rosuvastatin 10 mg tablet. for Major Depressive Disorder

The goal of this clinical trial is to learn if drug Rosuvastatin 10 mg works to treat major depression in adults. It will also learn about the safety of Rosuvastatin 10 mg .The main questions it aims to answer are: Does Rusovastatin lower the score of The Montgomery Asberg Depression Rating Scale (MADRS) among adult participants with Major Depression Disorder ( major depression )?

NCT06698666 · Official ClinicalTrials.gov record · Ain Shams University

RecruitingPhase 4Edmonton, Alberta
Phase 4: testing Tezepelumab for Severe Asthma

Adults with severe asthma may have sudden worsening shortness of breath that results in their going to Emergency Department for urgent care. Emergency Room visits for asthma management across Alberta have been reviewed and it has been found that adults frequently need to return for repeated worsening.

NCT06705764 · Official ClinicalTrials.gov record · University of Alberta

RecruitingPhase 3Milford, Connecticut
Phase 3: testing Racemic ketamine for Depression

This study wants to compare the relative effectiveness, acceptability, and side effects of ketamine delivered through an IV (a drip into the arm) which is not currently FDA approved for use in the treatment of treatment-resistant depression (TRD) and Esketamine (Spravato®), taken as a nasal spray which has received FDA approval for use in the treatment of treatment-resistant depression (TRD) in the treatment of patients with treatment-resistant depression (TRD). The study will look at the following: * How well the treatment helps with symptoms of depression (effectiveness), * How comfortable and willing people are to use the treatment (acceptability), and * How well people can deal with any side effects from the treatment (tolerability).

NCT06713616 · Official ClinicalTrials.gov record · Yale University

RecruitingPhase 2 / Phase 3Edmonton, Alberta
Phase 2 / Phase 3: testing Taurine for Long COVID

The COVID-19 pandemic has swept across the globe, affecting millions of individuals with varying degrees of severity. While many individuals recover from the acute phase of the infection, a significant proportion continue to experience persistent and debilitating symptoms long after the initial SARS-CoV-2 infection.

NCT06721949 · Official ClinicalTrials.gov record · University of Alberta

RecruitingPhase 1 / Phase 2Suzhou, Jiangsu
Phase 1 / Phase 2: testing TP04HN106 for Amyotrophic Lateral Sclerosis

This trial adopts a multicenter, randomly assigned, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment parallel design. This experiment is divided into two groups: the experimental drug group and the dummy treatment (placebo) group.

NCT06726577 · Official ClinicalTrials.gov record · Talengen Institute of Life Sciences, Shenzhen, P.R. China.

RecruitingNot a traditional drug phaseFairway, Kansas
Not a traditional drug phase: CuidaTEXT for Alzheimer Disease

The goal of this randomly assigned clinical trial it to test the how well it works of CuidaTEXT, the first Alzheimer's disease and Related Dementias (ADRD) caregiver support intervention to capitalize on text messaging, among Latinos. Researchers will compare those who receive the CuidaTEXT intervention to those who do not receive the intervention to see if CuidaTEXT effects Latino caregiver stressors and their negative consequences .

NCT06728436 · Official ClinicalTrials.gov record · University of Kansas Medical Center

RecruitingNot a traditional drug phaseHangzhou, Zhejiang
Not a traditional drug phase: testing Lecanemab 10 mg/kg for Alzheimer Disease

As the population increases and aging intensifies, cognitive disorders represented by Alzheimer's disease (AD) not only pose a severe threat to public health but also bring significant social and economic burdens. Previously, treatment options for Alzheimer's disease were very limited, mainly providing symptomatic relief with few available medications.

NCT06741553 · Official ClinicalTrials.gov record · Second Affiliated Hospital, Zhejiang University, School of Medicine

RecruitingPhase 3Phoenix, Arizona
Phase 3: testing IMA203 for Melanoma, Cutaneous Malignant

This clinical trial is a prospective, multicenter, open-label, randomly assigned, actively controlled, parallel-group Phase 3 clinical trial to measure the how well it works, whether it is safe and how hard side effects are to live with of treatment with IMA203 administered at the recommended phase 2 dose versus investigator's choice of treatment in patients with previously treated, unresectable or metastatic cutaneous melanoma or mucosal melanoma (MM). For patients interested in additional information on how to participate, please follow this link: https://mytomorrows.com/trials/suprame/en-us/

NCT06743126 · Official ClinicalTrials.gov record · Immatics US, Inc.

RecruitingPhase 4San Francisco, California
Phase 4: testing Suvorexant for Insomnia

PTSD affects approximately 22% of Veterans who have served in Iraq and Afghanistan. Symptoms of PTSD may include re-experiencing, avoidance of trauma reminders, negative thoughts or feelings, and hyperarousal, such as increased startle reactivity and disturbed sleep.

NCT06788522 · Official ClinicalTrials.gov record · VA Office of Research and Development

RecruitingNot a traditional drug phaseParis, Île-de-France Region
Not a traditional drug phase: testing Lenacapavir Injection for HIV I Infection

For most people with HIV (PWH), an effective antiretroviral regimen can be devised. However, some PWH have multiple treatment failures due to viral resistance or unacceptable side effects to medication and no longer have durable viral suppression.

NCT06799338 · Official ClinicalTrials.gov record · Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida

RecruitingPhase 3Birmingham, Alabama
Phase 3: testing Lanreotide for Pancreatic Carcinoma

This phase III trial compares the effect of using lanreotide before surgery to surgery alone in preventing pancreatic fistulas in patients with pancreatic cancer or a pancreatic lesion that could become cancerous. Lanreotide, a type of somatostatin analog similar to somatostatin (a hormone made by the body), and is used to treat certain types of gastroenteropancreatic neuroendocrine tumors, and carcinoid syndrome.

NCT06807437 · Official ClinicalTrials.gov record · SWOG Cancer Research Network

RecruitingPhase 1Basking Ridge, New Jersey
Phase 1: testing Sotorasib for Brain Tumor

The researchers are doing this study to find out how effective sotorasib is at getting into KRAS G12C+ brain tumors. The researchers will also find out whether sotorasib is a safe and effective treatment for people undergoing surgical resection of KRAS G12C+ metastatic brain tumors, and do tests that show how the body absorbs, distributes, and gets rid of sotorasib.

NCT06807619 · Official ClinicalTrials.gov record · Memorial Sloan Kettering Cancer Center

RecruitingNot a traditional drug phaseParis, Paris
Not a traditional drug phase: virtual reality for Chronic Obstructive Pulmonary Disease

Chronic respiratory diseases, such as Chronic Obstructive Pulmonary Disease (COPD), are a leading cause of death globally. These diseases not only contribute significantly to mortality but also lead to a decline in physical capacity, limiting daily activities and perpetuating a vicious cycle of deconditioning.

NCT06811402 · Official ClinicalTrials.gov record · Fondation Hôpital Saint-Joseph

RecruitingPhase 1 / Phase 2Beverly Hills, California
Phase 1 / Phase 2: testing BNT323 for Locally Advanced Breast Cancer

This is a Phase I/II, multi-site, open-label, two-part study designed to measure the how well it works, safety, optimized dose and contribution of components of BNT323 (also known as trastuzumab pamirtecan and DB-1303) in combination with BNT327 (also known as pumitamig and PM8002) in participants with hormone receptor-positive (HR+) or hormone receptor-negative (HR-), Human epidermal growth factor receptor (HER)2-positive, HER2-low (immunohistochemistry \[IHC\] 1+ or IHC 2+/in situ hybridization -), HER2-ultralow (IHC 0, with membrane staining) or HER2-null breast cancer (BC), or triple-negative breast cancer (TNBC).

NCT06827236 · Official ClinicalTrials.gov record · BioNTech SE

RecruitingNot a traditional drug phaseAnning
Not a traditional drug phase: testing benralizumab for Severe Eosinophilic Asthma

The objective of this study is to collect empirical data that elucidates the clinical profile and therapeutic how well it works of benralizumab among the patients aged 12 years and above, with severe eosinophilic asthma. The study will focus on the early treatment response, treatment outcomes and the change in asthma control of benralizumab therapy in a real-world setting in China.

NCT06862206 · Official ClinicalTrials.gov record · AstraZeneca

RecruitingPhase 4La Jolla, California
Phase 4: testing Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL for Drug Interactions

Polypharmacy and drug-drug interactions often limit statin optimization, including in a population of patients prescribed cytochrome P3A4 inhibitors such as, immunosuppressive agents, protease inhibitors, and antifungals. These patients frequently have autoimmune conditions or rheumatologic disorders that require complex drug regimens and are often on low-dose statin therapy or no statin at all, resulting in suboptimal LDL levels despite increased cardiovascular (CV) risk.

NCT06865885 · Official ClinicalTrials.gov record · University of California, San Diego

RecruitingNot a traditional drug phaseBeijing
Not a traditional drug phase: testing Lecanemab treatment group for Alzheimer&#39;s Disease

Alzheimer's disease (AD) manifests itself in cognitive decline, impaired ability to perform daily life, and a variety of behavioral and psychiatric symptoms, seriously endangering the health of the elderly. The prevalence and disability rates of AD in China remain high, and the lack of effective treatment options has brought a heavy burden to patients and their families.

NCT06871839 · Official ClinicalTrials.gov record · Cuibai Wei,Clinical Professor

RecruitingPhase 4Prague
Phase 4: testing Faricimab Injection for Wet Age-related Macular Degeneration

This is a prospective, randomly assigned study that compares 8-week and 12-week follow-up intervals after the 4 monthly injections in the loading phase. Patients with active CNV confirmed on optical coherence tomography (OCT) and OCT angiography (OCTA) will be randomly assigned into two groups and followed for 44 to 56 weeks.

NCT06875245 · Official ClinicalTrials.gov record · Faculty Hospital Kralovske Vinohrady

RecruitingNot a traditional drug phaseRome, Lazio
Secondary and Tertiary Digital Prevention of Non-alcoholic and Dysmetabolic Liver Disease

The prevalence of Metabolic dysfunction-associated steatotic liver disease (MASLD) and its severe form, Metabolic dysfunction-associated steatohepatitis (MASH), is high and they are increasingly becoming major causes of cirrhosis, hepatocellular carcinoma (HCC), and the need for liver transplantation. Due to the lack of noticeable symptoms during the early stages, the detection of MASLD is often delayed until the disease has advanced.

NCT06879236 · Official ClinicalTrials.gov record · Fondazione Policlinico Universitario Agostino Gemelli IRCCS

RecruitingNot a traditional drug phaseGenova
Not a traditional drug phase: High-tech rehabilitative treatment for Amyotrophic Lateral Sclerosis

The primary objective is to demonstrate, in a population of chronic neuromuscular disease the non-inferiority of a rehabilitation treatment integrated with robotic and/or technological devices compared to traditional rehabilitation treatment in the level of fatigue. The main question it aims to answer is: Are high-tech rehabilitation interventions, including robotic systems, virtual reality, and stabilometric platforms, not inferior to traditional rehabilitation methods in improving balance, motor function, fatigue levels, sarcopenia, cognitive engagement, and overall quality of life in patients with chronic neuromuscular diseases (NMDs)?

NCT06881979 · Official ClinicalTrials.gov record · Istituti Clinici Scientifici Maugeri SpA

RecruitingPhase 2 / Phase 3Ottawa, Ontario
Phase 2 / Phase 3: testing ketamine hydrochloride for Suicidal Ideation

The goal of this clinical trial is to treat active suicidal ideation in individuals with Major Depressive Disorder (major depression) using ketamine and to understand suicidal ideation by examining biological mechanisms using magnetic resonance imaging (MRI), and psychological mechanisms through validated clinical scales and qualitative interviews. The main questions it aims to answer are: 1.

NCT06891300 · Official ClinicalTrials.gov record · The Royal's Institute of Mental Health Research

RecruitingNot a traditional drug phaseChicago, Illinois
Not a traditional drug phase: testing Dupilumab - Standard Dose for Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)

The goal of this watch-and-measure (no experimental treatment required) study is to learn what can predict the return of the sense of smell in patients with chronic rhinosinusitis with nasal polyps being treated with dupilumab. The main questions it aims to answer are: 1.

NCT06892704 · Official ClinicalTrials.gov record · Northwestern University

RecruitingPhase 2Phoenix, Arizona
Phase 2: testing Cabozantinib for Locally Advanced Adrenal Cortical Carcinoma

This phase II trial compares the effect of giving cabozantinib with or without cemiplimab in patients with adrenocortical cancer that has spread to nearby tissue or lymph nodes (locally advanced), and that cannot be removed by surgery (unresectable) or that has come back after a period of improvement (recurrent) or that has spread from where it first started (primary site) to other places in the body (metastatic). Cabozantinib is in a class of medications called tyrosine kinase inhibitors.

NCT06900595 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)

RecruitingPhase 3Birmingham, Alabama
Phase 3: testing zolbetuximab for Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer

Zolbetuximab is being studied in people with cancer in and around the stomach or where the food pipe (esophagus) joins the stomach, called gastroesophageal junction (GEJ) cancer. Zolbetuximab with chemotherapy may be used to treat stomach and GEJ cancer when the cancer cells do not have a protein called HER2 (human epidermal growth factor receptor 2) on their surface (HER2-negative) but do have a protein called Claudin 18.2 (Claudin 18.2-positive).

NCT06901531 · Official ClinicalTrials.gov record · Astellas Pharma Global Development, Inc.

RecruitingPhase 2Baltimore, Maryland
Phase 2: testing ZEN-3694 for Metastatic Castration-resistant Prostate Cancer

This research is being done to determine if receiving the combination of testosterone and ZEN-3694 followed by the combination of enzalutamide plus ZEN-3694 will decrease the size of tumors in patients with prostate cancer that has become resistant to castration and other therapies. The investigators also want to determine if dosing first with the combination of testosterone and ZEN-3694 may cause enzalutamide and ZEN-3694 to work more effectively.

NCT06922318 · Official ClinicalTrials.gov record · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

RecruitingNot a traditional drug phaseCastellana Grotte, Bari
Not a traditional drug phase: Combined Exercise Program + A specific nutritional plan for individuals with IBS for Fibromyalgia

Fibromyalgia (FM) is a chronic disorder marked by widespread musculoskeletal pain, fatigue, sleep disturbances, and cognitive difficulties. Patients often experience hyperalgesia, allodynia, and muscle weakness.

NCT06923800 · Official ClinicalTrials.gov record · Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis

RecruitingNot a traditional drug phaseOmaha, Nebraska
Not a traditional drug phase: Heat therapy for Long COVID

Post-acute sequelae of SARS-CoV-2 infection (PASC) is becoming a major risk factor for chronic diseases, with older adults and those with underlying health conditions at risk of developing persistent mobility limitations and disabilities. Although exercise intervention is a common strategy to restore functional capacity, it may not be feasible or enticing to many people with PASC.

NCT06928116 · Official ClinicalTrials.gov record · University of Nebraska

RecruitingPhase 3Glendale, Arizona
Phase 3: testing KarXT for Bipolar Disorder Type I With Mania

This is a phase 3, open-label extension study to assess the long-term safety of KarXT for the treatment of mania or mania with mixed features in Bipolar-I disorder (BP-I) The primary objective of the study is to measure the long-term whether it is safe and how hard side effects are to live with of KarXT in the treatment of participants with mania or mania with mixed features associated with BP-I.

NCT06929273 · Official ClinicalTrials.gov record · Bristol-Myers Squibb

RecruitingNot a traditional drug phaseCalgary, Alberta
Not a traditional drug phase: Dynamic neural retraining system for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

We are studying the effect of a mind-body treatment for people with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) with or without Long COVID (LC). Our team recognizes that ME/CFS and Long COVID are serious, debilitating, biomedical conditions.

NCT06933173 · Official ClinicalTrials.gov record · University of Alberta

RecruitingNot a traditional drug phaseEast Providence, Rhode Island
Not a traditional drug phase: Team-delivered, exposure-based CBT for Obsessive Compulsive Disorder (OCD)

This study wants to test how the delivery of Cognitive Behavioral Therapy (CBT) for pediatric anxiety and OCD via different methods might increase its availability and effectiveness. CBT involves teaching the patient skills to enable them to gradually come into contact with feared situations.

NCT06934525 · Official ClinicalTrials.gov record · Bradley Hospital

RecruitingNot a traditional drug phaseValencia, Valencia
Not a traditional drug phase: Usual Care Group for Morbid Obesity

This clinical trial aims to determinate whether a structured exercise program, supported by telerehabilitation, can help individuals with severe obesity who are going to undergo bariatric surgery. The main objective of this study is whether a structured exercise program, including both supervised and home-based workouts, leads to greater body fat loss and improved strength compared to usual care.

NCT06934681 · Official ClinicalTrials.gov record · Instituto de Investigacion Sanitaria La Fe

RecruitingPhase 3Dothan, Alabama
Phase 3: testing Mirikizumab for Ulcerative Colitis

The main purpose of this study is to show whether in these individuals, treatment with both mirikizumab and tirzepatide, compared with treatment with mirikizumab and dummy treatment (placebo), leads to decrease or disappearance of UC symptoms, and loss of at least one-tenth of the overall body weight. Participation in this study will last up to 61 weeks, including 52 weeks of treatment.

NCT06937086 · Official ClinicalTrials.gov record · Eli Lilly and Company

RecruitingPhase 2Vancouver, British Columbia
Phase 2: testing psilocybin (25 mg) for Bipolar II Depression

This study is a 12-week (in addition to up to 30 days of screening) randomly assigned, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment, parallel-group trial. The primary objective of this study is to assess the effectiveness, safety, and tolerability of single-dose psilocybin (25 mg)-assisted therapy in comparison to active dummy treatment (placebo) (1 mg micro-dose) psilocybin-assisted therapy in patients with bipolar II depression who have not responded to adequate trials with at least two first or second-line treatments for bipolar II depression (i.e.

NCT06943573 · Official ClinicalTrials.gov record · Lakshmi N Yatham

RecruitingPhase 3Little Rock, Arkansas
Phase 3: testing KarXT for Bipolar Disorder Type I With Mania or Mania With Mixed Features

This is a Phase 3, randomly assigned, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment, multicenter, inpatient study in participants with bipolar disorder experiencing an acute episode of mania or mania with mixed features. The primary objective of the study is to measure the how well it works of KarXT compared to dummy treatment (placebo) in treating symptoms of mania during a 3-week inpatient period.

NCT06951711 · Official ClinicalTrials.gov record · Bristol-Myers Squibb

RecruitingNot a traditional drug phaseLebanon, New Hampshire
Not a traditional drug phase: Home Based Self- management and Cognitive Training Changes lives in Multiple Sclerosis (HOBSCOTCH-MS) for Multiple Sclerosis

This study wants to assess the ability of the home-based intervention, HOBSCOTCH-MS to improve the quality of life and cognitive function in Service Members, Veterans and civilians who have multiple sclerosis with cognitive and memory problems (MS participants). This study will also assess the ability of the HOBSCOTCH-MS program to improve quality of life in caregivers of patients with multiple sclerosis and to reduce caregiver burden.

NCT06951919 · Official ClinicalTrials.gov record · Dartmouth-Hitchcock Medical Center

RecruitingPhase 3Mobile, Alabama
Phase 3: testing Pembrolizumab for Endometrial Cancer

Researchers are looking for new ways to treat people with proficient mismatch repair (pMMR) endometrial cancer (EC) that is advanced or recurrent. * EC is a type of cancer that starts in the tissues inside the uterus (womb) * pMMR indicates that certain normal proteins are present in the cancer cells * Advanced means the cancer has spread locally or to other parts of the body (metastatic) and cannot be removed with surgery * Recurrent means the cancer came back after surgery Sacituzumab tirumotecan (also known as sac-TMT) and pembrolizumab are the study medicines.

NCT06952504 · Official ClinicalTrials.gov record · Merck Sharp & Dohme LLC

RecruitingPhase 3Gilbert, Arizona
Phase 3: testing Sacituzumab tirumotecan for Breast Neoplasms

Researchers are looking for new ways to treat types of breast cancer that are both: * High-risk, which means the cancer may have a higher chance of getting worse or coming back after treatment * Early-stage, which means the cancer is in the breast or the lymph nodes around the breast The 2 types of breast cancer in this study are triple-negative breast cancer (TNBC) and hormone receptor (HR)-low positive/human epidermal growth factor receptor-2 (HER2) negative breast cancer. These cancers have zero or a low amount of a protein called HER2 and other proteins that attach to the hormones estrogen or progesterone.

NCT06966700 · Official ClinicalTrials.gov record · Merck Sharp & Dohme LLC

RecruitingNot a traditional drug phaseCharlestown, Massachusetts
Not a traditional drug phase: FDG-PET/fMRI/EEG imaging for Epilepsy

This study aims to better understand how epilepsy alters brain function through neuroimaging of healthy people and people with epilepsy. The study investigates how changes in brain metabolism (sugar consumption, measured by positron emission tomography \[FDG-PET\], and blood flow, measured by functional magnetic resonance imaging \[fMRI\]) relate to abnormal interictal electrical activity associated with epilepsy (measured by electroencephalography \[EEG\]).

NCT06974305 · Official ClinicalTrials.gov record · Massachusetts General Hospital

RecruitingNot a traditional drug phaseDuarte, California
Not a traditional drug phase: Interview for Head and Neck Carcinoma

This clinical trial tests how well a three-dimensional (3D) mindfulness virtual reality (VR) versus (vs) two-dimensional (2D) non-immersive interventions works in improving depression, anxiety, pain, and/or stress in patients with head and neck cancer (HNC) undergoing radiation or chemoradiation (C/RT), and their caregivers. HNC patients undergoing C/RT can experience higher levels of depression, anxiety, distress and pain that negatively impact their quality of life.

NCT06985784 · Official ClinicalTrials.gov record · City of Hope Medical Center

RecruitingPhase 3Toronto, Ontario
Phase 3: MagPro X100/R30 stimulator, Cool-B70 coil for Bipolar Depression Depressed Phase

The purpose of this trial is to conduct an adequately powered clinical trial of once daily LFR for individuals diagnosed with treatment-resistant BD-DE who have not responded to iTBS or sham treatment applied to the left DLPFC. This work will develop the evidence supporting the use of LFR rTMS for individuals with treatment-resistant BD-DE who currently have limited treatment options to alleviate their suffering.

NCT06986460 · Official ClinicalTrials.gov record · Tyler Kaster

RecruitingPhase 1Duarte, California
Phase 1: testing Busulfan for Acute Myeloid Leukemia

This phase I trial tests the safety, side effects and effectiveness of emapalumab with post-transplant cyclophosphamide, tacrolimus, and mycophenolate mofetil in preventing graft-versus-host disease (GVHD) in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) after reduced-intensity donor (allogeneic) hematopoietic cell transplant (HCT). Giving chemotherapy, such as fludarabine, melphalan, or busulfan, before a donor \[peripheral blood stem cell\] transplant helps kill cancer cells in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow.

NCT06996119 · Official ClinicalTrials.gov record · City of Hope Medical Center

RecruitingPhase 2Birmingham, Alabama
Phase 2: testing RE104 for Injection for Adjustment Disorder

This study wants to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms or depressive symptoms mixed with anxiety symptoms in participants with Adjustment Disorder due to cancer or other illnesses such as Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), Parkinson's Disease (PD) or Idiopathic Pulmonary Fibrosis (IPF) as compared to active-dummy treatment (placebo).

NCT07002034 · Official ClinicalTrials.gov record · Reunion Neuroscience Inc

RecruitingNot a traditional drug phaseCleveland, Ohio
Not a traditional drug phase: Clubhouse Model of Psychosocial Rehabilitation for Serious Mental Illness for Schizophrenia

This study wants to understand how different types of community-based mental health care affect thinking abilities, daily functioning, and brain activity in adults with schizophrenia and related conditions. The investigators are especially interested in learning whether the Clubhouse Model-a structured, supportive community for individuals with mental illness-has unique benefits compared to standard outpatient mental health services.

NCT07006935 · Official ClinicalTrials.gov record · Case Western Reserve University

RecruitingPhase 3Mesa, Arizona
Phase 3: testing Surabgene Lomparvovec (ABBV-RGX-314) for Neovascular Age-related Macular Degeneration

Neovascular age-related macular degeneration (nAMD), also known as "wet" AMD, is the abnormal growth of new blood vessels in the light-sensitive tissue at the back of the eye called the retina. this study wants to assess how safe and effective Surabgene Lomparvovec is in treating participants with Neovascular age-related macular degeneration (nAMD).

NCT07007065 · Official ClinicalTrials.gov record · AbbVie

RecruitingPhase 2Little Rock, Arkansas
Phase 2: testing Tezepelumab for Peanut Allergy

The proposed study is a proof-of-concept Phase 2, neither you nor the study doctors know who gets the real treatment, randomly assigned compared with a dummy treatment clinical trial evaluating the safety and how well it works of tezepelumab and peanut Oral Immunotherapy (OIT) for the treatment of peanut allergy. Study participation is divided into 3 periods: (i) a this drug alone period comprised of injections of either Tezepelumab or dummy treatment (placebo) from week 0 to week 8, (ii) followed by a combination therapy period comprised of 56 weeks during which peanut OIT is built up and maintained, and (iii) a treatment withdrawal period comprised of 12 weeks.

NCT07015996 · Official ClinicalTrials.gov record · National Institute of Allergy and Infectious Diseases (NIAID)

RecruitingNot a traditional drug phaseNijmegen, Gelderland
SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)

The goal of this watch-and-measure (no experimental treatment required) study is to comprehensively profile six immune-mediated inflammatory diseases, including atopic dermatitis (AD), plaque psoriasis (PSO), hidradenitis suppurativa (HS), cutaneous T-cell lymphoma subtype mycosis fungoides (MF), chronic spontaneous urticaria (CSU), and cutaneous lupus erythematosus (CLE) in daily practice. Data will be compared with data from healthy volunteers.

NCT07021495 · Official ClinicalTrials.gov record · Leiden University Medical Center

RecruitingNot a traditional drug phaseBozeman, Montana
Not a traditional drug phase: Speech-Gesture combinations for Autism Disorder

This research study investigates how hand gestures can support language comprehension and communication skills of hearing speaking, non-speaking, and/or minimally verbal individuals with Autism Spectrum Disorders (ASD), who are especially disadvantaged by the lack of accessible services in their rural communities. Individuals with other cognitive profiles, including Developmental Language Disorder (DLD), ADHD, Dyslexia, and others are welcome too.

NCT07054866 · Official ClinicalTrials.gov record · Montana State University

RecruitingNot a traditional drug phaseSt. John's, Newfoundland and Labrador
Not a traditional drug phase: Action-Based Cognitive Remediation for Psychosis

Psychotic disorders impact 4.6 people per 1000 globally, with approximately 1.5 million Canadians affected. The age of onset for psychotic disorders often begin during the critical years of youth and early adulthood, resulting in significant challenges for individuals and their families, including difficulties with thinking, relationships, and overall well-being.

NCT07056894 · Official ClinicalTrials.gov record · Nova Scotia Health Authority

RecruitingPhase 2 / Phase 3Wilmington, Delaware
Phase 2 / Phase 3: testing Enlicitide Decanoate for Heterozygous Familial Hypercholesterolemia (HeFH)

This study is designed to learn if enlicitide decanoate is safe and effective to treat children and adolescents with heterozygous familial hypercholesterolemia (HeFH) and high amounts of low-density lipoprotein cholesterol (LDL-C) in the blood. The goals of this study are to learn about the safety of enlicitide and if children tolerate it, what happens to enlicitide in a child's body over time, and if enlicitide works to lower cholesterol levels in children more than a dummy treatment (placebo).

NCT07058077 · Official ClinicalTrials.gov record · Merck Sharp & Dohme LLC

RecruitingNot a traditional drug phaseDublin, California
Not a traditional drug phase: Exercise intervention for Localized Malignant Solid Neoplasm

This clinical trial studies whether an exercise program can be successfully delivered to patients receiving treatment for cancer through virtual sessions and allow patients to exercise in their own home. Treatments for cancer can cause side effects such as fatigue and loss of strength.

NCT07059884 · Official ClinicalTrials.gov record · Alliance for Clinical Trials in Oncology

RecruitingPhase 3Daphne, Alabama
Phase 3: testing Patritumab deruxtecan for Breast Neoplasms

Researchers are looking for other ways to treat breast cancer (BC) that is hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) and either unresectable locally advanced or metastatic. * HR positive (HR+) means the cancer cells have proteins that attach to estrogen or progesterone (hormones) which help the cancer to grow and spread * HER2 negative (HER2-) means the cancer cells have a low amount of a protein called HER2 * Unresectable locally advanced means the cancer cannot be completely removed by surgery and has spread into nearby tissue or muscles * Metastatic means the cancer has spread to other parts of the body Treatment for this type of breast cancer usually includes endocrine therapy (ET) and sometimes a second treatment.

NCT07060807 · Official ClinicalTrials.gov record · Merck Sharp & Dohme LLC

RecruitingNot a traditional drug phaseMessina, Italy/Me
Not a traditional drug phase: CAREN for Healthy Individuals (Controls)

The goal of this clinical trial is to investigate motor responses in healthy subjects and patients with movement disorders, brain and spinal cord injury, neuromuscular diseases, or cardiovascular diseases. This study aims to measure the effectiveness of traditional physical activities combined with innovative interventions such as cryotherapy, ultrasound therapy, laser therapy, transcranial magnetic stimulation (TMS), and transcranial direct current stimulation (tDCS).

NCT07066137 · Official ClinicalTrials.gov record · IRCCS Centro Neurolesi Bonino Pulejo

RecruitingNot a traditional drug phaseAthens
Mechanisms of Response and Resistance to Innovative Treatments in Patients With Locally Advanced or Metasta…

Ample evidence has highlighted the significant clinical benefit of novel therapies for many patients with advanced breast cancer (aBC). The use of CDK inhibitors, antibody-drug conjugates (ADCs), immune checkpoint inhibitors (ICIs), and PARP inhibitors as first-line or subsequent treatments has improved progression-free survival (PFS) rates compared to conventional therapies.

NCT07066917 · Official ClinicalTrials.gov record · Hellenic Cooperative Oncology Group

RecruitingPhase 4Chandigarh, Punjab
Phase 4: testing Phenytoin for Seizures

Rationale/gaps in existing knowledge: The prophylaxis for post-traumatic seizures (PTS) remains controversial due to a lack of class I evidence. Investigators plan to conduct a high-quality, prospective, multicentric, randomly assigned study regarding seizure prophylaxis in traumatic brain injury (TBI) with phenytoin, levetiracetam, and the dummy treatment (placebo) in three respective treatment groups, along with the effect of drug polymorphism on seizure occurrence.

NCT07072624 · Official ClinicalTrials.gov record · All India Institute of Medical Sciences, Jodhpur

RecruitingNot a traditional drug phaseLeeds, Greater Manchester
Not a traditional drug phase: Lab4p Probiotic Consortium for Impaired Glucose Tolerance (Prediabetes)

This 12-week, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment trial will examine whether daily supplementation with the Lab4P probiotic can improve cognitive performance and metabolic health in overweight and obese adults aged 18 to 40. Seventy you would be randomly assigned to receive either Lab4P or a dummy treatment (placebo).

NCT07073781 · Official ClinicalTrials.gov record · Leeds Beckett University

RecruitingPhase 3Los Angeles, California
Phase 3: testing Risvutatug rezetecan (Ris-Rez) for Neoplasms, Lung

In this study researchers are testing Risvutatug rezetecan also known as (Ris-Rez) a new medicine that targets specific proteins (B7-H3) on cancer cells, thereby reducing the cancer's ability to grow and spread. This study specifically aims to evaluate how well Ris-Rez works in treating relapsed SCLC compared to standard treatment topotecan, by checking whether Ris-Rez makes cancers smaller or disappear completely and if it helps participants live longer.

NCT07099898 · Official ClinicalTrials.gov record · GlaxoSmithKline

RecruitingNot a traditional drug phaseInnsbruck, Tyrol
Socio-cognitive and Biological Responses to Maltreatment

The study will investigate how a history of emotional childhood maltreatment (CM) is associated with different aspects of psychological (social behaviour, empathy) and biological (brain function and structure, inflammation) health. In fact, CM is a risk factor for many mental disorders, such as schizophrenia and autism.

NCT07101107 · Official ClinicalTrials.gov record · Medical University Innsbruck

RecruitingNot a traditional drug phaseBoston, Massachusetts
Not a traditional drug phase: Persistent air leak quantification for Persistent Air Leaks

Persistent air leaks (PALs) are a common postoperative complication resulting from tears in the visceral pleura or peripheral lung resections. Although highly prevalent with significant consequences, traditional assessment methods lack the capability to objectively quantify air leaks, which further complicates management, results in inconsistent decision making, and prolongs hospital stays.

NCT07105436 · Official ClinicalTrials.gov record · Kai Swenson

RecruitingPhase 2Gainesville, Florida
Phase 2: testing Glucagon-like peptide 1 receptor agonist for Endometrioid Endometrial Adenocarcinoma

This study will explore the use of glucagon-like peptide 1 receptor agonist (GLP-1RA) used concurrently with levonorgestrel intrauterine device in patients with poor surgical candidacy for a hysterectomy or patients who are pursuing fertility sparing. GLP-1RA are a class of medications that mimic the natural hormone glucagon-like peptide-1.

NCT07107334 · Official ClinicalTrials.gov record · University of Florida

RecruitingPhase 4Milwaukee, Wisconsin
Phase 4: testing GLP-1 agonists for Psoriatic Arthritis (PsA)

Psoriatic arthritis (PsA) is a chronic inflammatory condition that affects the joints but can also have an effect on multiple parts of the body. This study will assess if the effectiveness of Glucagon-like peptide-1 (GLP-1) medications used to treat type 2-diabetes and weight management, or nutrition counseling can better treat individuals with Psoriatic Arthritis who are also needing treatment for obesity and type 2 diabetes.

NCT07111494 · Official ClinicalTrials.gov record · Medical College of Wisconsin

RecruitingPhase 1Duarte, California
Phase 1: testing LY4257496 for Breast Neoplasms

The main purpose of this study is to evaluate safety, tolerability, and how well it works of LY4257496 alone and as part of relevant standard of care (SOC) combination therapy in participants with Gastrin-releasing Peptide Receptor (GRPR)-positive advanced cancer, including but not limited to breast, colorectal, prostate, endometrial, esophageal, gastroesophageal (GE) junction, and gastric cancer. The study will also measure the safety, tolerability, and how well it works of LY4257529 to identify cancer with high levels of a protein called GRPR.

NCT07114601 · Official ClinicalTrials.gov record · Eli Lilly and Company

RecruitingNot a traditional drug phaseBari, Bari
Not a traditional drug phase: Experimental arm: probiotic for Irritable Bowel Syndrome (IBS)

This clinical study aims to see if a specific combination of probiotics-Lactobacillus rhamnosus GG and Lactobacillus plantarum 299V-can help children and adolescents with Irritable Bowel Syndrome (IBS). IBS is a common digestive condition in children, causing abdominal pain, bloating, and changes in bowel habits (either diarrhoea, constipation, or alternating between the two).

NCT07125625 · Official ClinicalTrials.gov record · University of Bari

RecruitingPhase 1 / Phase 2Shanghai, Shanghai Municipality
Phase 1 / Phase 2: testing T-DXd for Breast Cancer

Multiple trials confirm systemic T-DXd how well it works in HER2+ breast cancer with leptomeningeal/brain metastases, yet median LM survival remains 3-4 months, highlighting unmet needs. While systemic therapies improve survival, intracranial disease control remains limited due to poor BBB penetration.

NCT07134153 · Official ClinicalTrials.gov record · Fudan University

RecruitingPhase 4Edmonton, Alberta
Phase 4: testing Sotatercept for Pulmonary Artery Hypertension

The goal of this clinical trial is to determine whether sotatercept is effective in improving diffusing capacity in patients with pulmonary arterial hypertension. you would be asked to: * Take Sotatercept every 21 days (±3 days) * Each you would be enrolled in the study for 29 Weeks * Visit the clinic 18 times * Have a physical exam * Perform assessments of lung function and exercise tests * Have an ultrasound of their heart * Have blood draws done at regular intervals The main objectives of the study are: Primary objective: To assess whether sotatercept will improve recruitment of diffusing membrane capacity (DM) with exercise.

NCT07140484 · Official ClinicalTrials.gov record · University of Alberta

RecruitingNot a traditional drug phaseStrasbourg
Not a traditional drug phase: microcirculation using the video microscopy tool. for Cardiogenic Shock

Despite advancements in treatment, the mortality rate for cardiogenic shock (CS) remains high at around 50%. The EMPULSE-HF trial showed that early introduction of empagliflozin in stabilized patients with acute heart failure led to a composite benefit in mortality, rehospitalization, and quality of life.

NCT07141355 · Official ClinicalTrials.gov record · University Hospital, Strasbourg, France

RecruitingPhase 2Cambridge
Phase 2: testing dapansutrile for Parkinson Disease

In Parkinson's disease (PD), there is inflammation in the brain, the gut and the blood, which is thought to contribute to the development and progression of the disease. The Nod-like receptor (NLR) family pyrin domain containing 3 (NLRP3) inflammasome is a complex of proteins which plays a critical role in mediating inflammation, and there is growing evidence from laboratory research that the inflammasome plays a role in Parkinson's disease.

NCT07157735 · Official ClinicalTrials.gov record · Cambridge University Hospitals NHS Foundation Trust

RecruitingPhase 3Anniston, Alabama
Phase 3: MK-1406 for Influenza

Approximately one billion cases of seasonal influenza occur annually. Of these, 3 to 5 million illnesses are severe and responsible for up to 650,000 deaths per year (WHO 2025).

NCT07159763 · Official ClinicalTrials.gov record · Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

RecruitingNot a traditional drug phaseBath, Somerset
Not a traditional drug phase: observational study for Axial Spondylarthritis (axSpA)

This watch-and-measure (no experimental treatment required) study will target patients with axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) who have started treatment with bimekizumab, upadacitinib, risankizumab, guselkumab, or a tumour necrosis factor-alpha inhibitor (e.g., adalimumab or etanercept) at NHS hospitals in the United Kingdom. Information from patients' medical records will be collected, and patients will complete surveys about their experiences with their treatment.

NCT07166315 · Official ClinicalTrials.gov record · Adelphi Real World

RecruitingPhase 1New Haven, Connecticut
Phase 1: testing M0324 for Advanced Solid Tumor

The purpose of this first-in-human study is to identify a recommend dose(s) for subsequent larger studies (recommended dose(s) for expansion, RDE), examining increasing doses of M0324, primarily looking at safety, but also preliminary signs of how well it works, pharmacokinetics (PK), and pharmacodynamics (PD). Three different treatments with M0324 will be studied, M0324 as a this drug alone(Part 1), M0324 in combination with pembrolizumab (Part 2), and in combination with mFOLFIRINOX (a chemotherapy treatment)(Part 3).

NCT07166601 · Official ClinicalTrials.gov record · EMD Serono Research & Development Institute, Inc.

RecruitingNot a traditional drug phaseJacksonville, Florida
Not a traditional drug phase: testing GLP-1 Receptor Agonists for Polycystic Ovarian Syndrome in Adolescent Females

The prevalence of childhood obesity in the United States has more than tripled in the past four decades affecting one in every five adolescent girls and is disproportionally higher among racial and/or ethnic minorities. Normal puberty onset and progression is dependent on normal hypothalamic-pituitary-gonadal (HPG) axis which is affected by whole body metabolism.

NCT07169136 · Official ClinicalTrials.gov record · Nemours Children's Clinic

RecruitingPhase 3Montpellier
Phase 3: testing Platform therapies (Dimethyl Fumarate, Teriflunomide, Glatiramer Acetate, Beta-interferons) for Relapsing-Remitting Multiple Sclerosis (RRMS)

Multiple sclerosis (MS), the main central nervous system autoimmune disorder, is the first cause of non-traumatic disability in young adults and has thus significant individual consequences with elevated public health cost. It commonly starts during the third and fourth decades.

NCT07189325 · Official ClinicalTrials.gov record · University Hospital, Montpellier

RecruitingPhase 3Fresno, California
Phase 3: testing Zongertinib for Non-small Cell Lung Cancer

Beamion LUNG-3 study evaluates whether zongertinib, an oral HER2-targeted treatment, can improve outcomes compared with standard adjuvant treatment in adults with completely resected Stage II-IIIB non-small cell lung cancer (NSCLC) whose tumors have activating HER2 tyrosine kinase domain (TKD) mutations. Eligible participants must have undergone curative-intent surgery and received guideline-appropriate perioperative systemic therapy, either neoadjuvant platinum-based chemotherapy with or without immunotherapy, or adjuvant platinum-based chemotherapy.

NCT07195695 · Official ClinicalTrials.gov record · Boehringer Ingelheim

RecruitingNot a traditional drug phaseChapel Hill, North Carolina
Not a traditional drug phase: Brief Behavioral Treatment for Insomnia (BBTI) for Post-traumatic Stress Disorder

The main objective of this pilot trial is to assess the feasibility and preliminary how well it works of telehealth-delivered behavioral therapy to reduce the development of posttraumatic stress and depressive symptoms following motor vehicle collision among individuals at high risk. This pilot trial will provide the data necessary to design and support a large-scale trial.

NCT07196332 · Official ClinicalTrials.gov record · University of North Carolina, Chapel Hill

RecruitingNot a traditional drug phaseMunich, Bavaria
Not a traditional drug phase: Intermittent theta-burst stimulation (iTBS) using PowerMAG 100 ppTMS for Depressive Disorder

This is a monocentric, randomly assigned pilot study conducted at the Max Planck Institute of Psychiatry, Munich. The study investigates the effects of two different intermittent theta-burst stimulation (iTBS) schedules on biological and clinical outcomes in patients with depression and comorbid Post-COVID-19 condition (PCC).

NCT07197138 · Official ClinicalTrials.gov record · Max-Planck-Institute of Psychiatry

RecruitingNot a traditional drug phaseJohannesburg
Not a traditional drug phase: "Undetectable & You" HIV treatment literacy app for HIV

Undetectable = Untransmittable (U=U) is the scientific consensus that people with human immunodeficiency virus (HIV) who achieve viral suppression through antiretroviral treatment (ART) cannot transmit the virus sexually. While global studies confirm this, awareness of U=U remains very limited in sub-Saharan Africa, including South Africa, where only two-thirds of people living with HIV (PLHIV) are virally suppressed despite having the largest treatment program globally.

NCT07199634 · Official ClinicalTrials.gov record · Boston University

RecruitingPhase 1Birmingham, Alabama
Phase 1: testing PF-08052667 for Non-muscle Invasive Bladder Cancer

This study wants to learn how a new medicine called PF-08052667 works when used by itself or together with another medicine called Bacillus Calmette Guerin (BCG), and/or a medicine called sasanlimab. This study is for adults who have a type of bladder cancer that hasn't spread into the muscle layer of the bladder but is more likely to come back or grow.

NCT07206225 · Official ClinicalTrials.gov record · Pfizer

RecruitingNot a traditional drug phaseHamilton, Ontario
Not a traditional drug phase: Group-Based Psychoeducation for Bipolar Disorder (BD)

People with bipolar disorder (BD) are at high risk of relapse following hospital discharge, partly due to a lack of BD-specific expertise and resources within community services required for comprehensive treatment. Although clinical guidelines recommend combining medication and psychosocial support, and research shows that early intervention is associated with improved outcomes, no structured care programs currently exist for individuals in the early stages of BD, contributing to chronic illness progression and preventable hospitalizations.

NCT07213492 · Official ClinicalTrials.gov record · McMaster University

RecruitingNot a traditional drug phaseSan Francisco, California
Not a traditional drug phase: Trigeminal Nerve Stimulation for Attention Deficit Disorder With Hyperactivity (ADHD)

The goal of this clinical trial is to learn if external trigeminal nerve stimulation (eTNS) works to treat ADHD symptoms in children on the autism spectrum (ASD). It will also learn about the how well it works and tolerability of the eTNS device.

NCT07214545 · Official ClinicalTrials.gov record · University of California, San Francisco

RecruitingNot a traditional drug phaseDetroit, Michigan
Not a traditional drug phase: Peer Activate for Major Depressive Disorder

Low-income individuals have limited access to evidence-based interventions for mental health. Peer recovery specialists, individuals in recovery from mental health and/or substance use problems, have the potential to increase access to evidence-based interventions for individuals from low-resource communities, particularly when trained and supervised in models that are acceptable and feasible in these communities.

NCT07219394 · Official ClinicalTrials.gov record · Wayne State University

RecruitingPhase 1 / Phase 2East York, Ontario
Phase 1 / Phase 2: testing ARO-MAPT-SC for Alzheimer Disease

Trial to measure the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ARO-MAPT-SC compared to dummy treatment (placebo) in adult healthy volunteers and in participants with early Alzheimer's disease (AD), defined as mild cognitive impairment due to AD and mild AD dementia, as well as primary tauopathies, including microtubule associated protein tau -related frontotemporal dementia (MAPT-FTD) and progressive supranuclear palsy- Richardson syndrome (PSP-RS).

NCT07221344 · Official ClinicalTrials.gov record · Arrowhead Pharmaceuticals

RecruitingPhase 3Atlanta, Georgia
Phase 3: testing Linvoseltamab for Relapsed and/or Refractory Multiple Myeloma (RRMM)

This study is researching a drug called linvoseltamab (also called "study drug") either given alone or in combination with another anti-myeloma drug called carfilzomib, compared to several standard treatments for progressive Multiple Myeloma (MM) after at least 1 but no more than 3 prior therapies. The aim of this study is to see if the safety and how well it works of linvoseltamab alone or in combination with carfilzomib can deliver better outcomes (deeper and longer responses that help extend life) than standard treatment options.

NCT07222761 · Official ClinicalTrials.gov record · Regeneron Pharmaceuticals

RecruitingPhase 3New York, New York
Phase 3: testing Fludarabine for B-cell Acute Lymphoblastic Leukemia

The researchers are doing this study to find out whether PK-targeted fludarabine is an effective Lymphodepletion (LD) chemotherapy approach for people with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) who will receive tisagenlecleucel CAR T-cell therapy. The researchers will compare PK-targeted fludarabine dosing with standard fludarabine dosing to see which treatment approach is more effective.

NCT07223021 · Official ClinicalTrials.gov record · Memorial Sloan Kettering Cancer Center

RecruitingNot a traditional drug phaseDallas, Texas
Not a traditional drug phase: N1 Implant for Tetraplegia/Tetraparesis

The VOICE Study is an early feasibility study to measure the initial clinical safety and how well it works of the N1 and R1 Systems device design concept in providing an ability to communicate. The Neuralink N1 Implant is intended to provide the ability to communicate to individuals with severe and irreversible speech production impairment.

NCT07224256 · Official ClinicalTrials.gov record · Neuralink Corp

RecruitingNot a traditional drug phaseColumbus, Ohio
Not a traditional drug phase: Ketogenic diet for PCOS (Polycystic Ovary Syndrome)

The SPARK- Pilot study (Symptoms of PCOS Ameliorated by Responses to Keto-adaptation) is a 12-week clinical trial at The Ohio State University designed to explore how different ways of achieving ketosis may improve reproductive and metabolic health in women with Polycystic Ovary Syndrome (PCOS). you would be randomly assigned to one of two groups: * A ketogenic diet group, following a low-carbohydrate, nutrient-dense meal plan.

NCT07227363 · Official ClinicalTrials.gov record · Ohio State University

RecruitingPhase 1Duarte, California
Phase 1: testing Cyclophosphamide for Follicular Helper T-Cell Lymphoma

This phase I trial tests the safety, side effects and best dose of ruxolitinib in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) chemotherapy and how well the combination works in treating patients with untreated nodal T-follicular helper (TFH) cell lymphoma. Ruxolitinib phosphate blocks a protein called janus kinase, which may help keep abnormal blood cells or cancer cells from growing.

NCT07278856 · Official ClinicalTrials.gov record · City of Hope Medical Center

RecruitingPhase 3Birmingham, Alabama
Phase 3: testing Mocertatug rezetecan for Neoplasms, Endometrial

This study specifically aims to evaluate how well mocertatug rezetecan (Mo-Rez) works in treating Endometrial Cancer (EC) compared to standard of care. The study also assesses whether Mo-Rez is safe and tolerated well by participants in comparison to standard of care and will help provide a better understanding of the main side effects of the drugs.

NCT07286331 · Official ClinicalTrials.gov record · GlaxoSmithKline

RecruitingPhase 1 / Phase 2Phoenix, Arizona
Phase 1 / Phase 2: testing Preventative (Prophylactic) Medication - Corticosteroids: Methylprednisolone for Amyotrophic Lateral Sclerosis

PIONEER-ALS is a Phase 1/2, multicenter, open-label, ascending dose, uncontrolled, first-in-human study that will measure the safety, tolerability and effects on clinical and biomarker endpoints of intracisternal administration of Vtx-002 in participants with Amyotrophic Lateral Sclerosis (ALS). Two escalating dose (low dose and high dose) cohorts are planned.

NCT07287397 · Official ClinicalTrials.gov record · Vector Y Therapeutics

RecruitingNot a traditional drug phaseLos Angeles, California
Not a traditional drug phase: nVNS Treatment for TMD

The study aims to examine the effects of transcutaneous non-invasive vagus nerve stimulation (nVNS) on symptoms and brain mechanisms in premenopausal women with temporomandibular disorders (TMD). Non-invasive vagus nerve stimulation (nVNS) is the most well researched and possibly the most effective non-invasive neuromodulation treatment for chronic pain conditions that targets the brain-gut-microbiome (BGM) axis.

NCT07288411 · Official ClinicalTrials.gov record · Arpana Church

RecruitingNot a traditional drug phaseMontpellier
Not a traditional drug phase: Monthly pNfL monitoring for Multiple Sclerosis (MS) - Relapsing-remitting

Reference MRI scan is recommended 6 months after treatment onset in patients with multiple sclerosis (MS), and follow-up scans at 12 months later to monitor subclinical activity. When monitoring treatment response in patients treated with disease modifying treatments (DMTs), the measurement of new or enlarging T2/FLAIR hyperintense lesions (NELs) is the preferred MRI method supplemented by contrast-enhancing lesions (CELs) for monitoring treatment response.

NCT07292480 · Official ClinicalTrials.gov record · Centre Hospitalier Universitaire de Nīmes

RecruitingPhase 4Columbus, Ohio
Phase 4: testing Insulin for Pregnancy, High Risk

PRISM is a single center non-inferiority randomly assigned controlled trial of permissive intrapartum glucose management (intervention) versus strict intrapartum glucose management (standard of care) among pregnant individuals with pregestational diabetes using hybrid closed loop therapy (HCL) who are admitted for labor management. you would be randomly assigned in a 1:1 fashion to one of two intrapartum glycemic control options: permissive (70-140 mg/dL) or strict (70-110 mg/dL).

NCT07293715 · Official ClinicalTrials.gov record · Ohio State University

RecruitingPhase 2New York, New York
Phase 2: testing Psilocybin for Stuttering

This Phase 2a clinical trial is an open-label, single-group, within-subjects pilot study designed to measure the safety, feasibility, and preliminary how well it works of psilocybin as a therapeutic intervention for adults with developmental stuttering. This pilot study will assess whether further research to explore the potential benefits of psilocybin-assisted therapy for improving clinical outcomes in individuals who stutter, is warranted.

NCT07296328 · Official ClinicalTrials.gov record · NYU Langone Health

RecruitingNot a traditional drug phaseMadrid, Madrid
Not a traditional drug phase: Inflammatory biomarker sample collection for Inflammation Biomarkers

The goal of this watch-and-measure (no experimental treatment required) study is to determine whether changes in the inflammatory profile of heart failure patients can help identify those who may have a worse prognosis or who might benefit more from specific treatments. In addition, we aim to explore whether certain genes or gene mutations are related to a higher risk of future cardiovascular problems.

NCT07320014 · Official ClinicalTrials.gov record · Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz

RecruitingPhase 4Boston, Massachusetts
Phase 4: testing Dapagliflozin (10Mg Tab) along with standard medical therapy for Lupus Nephritis (LN)

Lupus nephritis is a chronic and life-threatening autoimmune cause of kidney disease that predominately impacts young people and can lead to kidney failure. Sodium-glucose co-transporter-2 inhibitors, including dapagliflozin, are known to improve outcomes for people with other causes of chronic kidney disease.

NCT07323524 · Official ClinicalTrials.gov record · Brigham and Women's Hospital

RecruitingPhase 3Birmingham, Alabama
Phase 3: testing CARTISTEM® + Debridement for Knee Cartilage Defects

This study will test whether CARTISTEM is safe and works better than debridement (a surgery that cleans out damaged tissue) for people with knee cartilage damage and osteoarthritis. CARTISTEM is a new treatment made of stem cells from donated umbilical cord blood mixed with a gel (hyaluronic acid) that is placed in the damaged area of the knee The main goal is to find out if CARTISTEM® reduces knee pain and improves knee function more than debridement two years after treatment.

NCT07339111 · Official ClinicalTrials.gov record · Medipost, Inc.

RecruitingNot a traditional drug phaseIstanbul, Istanbul
Not a traditional drug phase: Synbiotic Supplement for PCOS (Polycystic Ovary Syndrome)

This study will look at whether a reduced-calorie Mediterranean-style eating plan, together with a synbiotic supplement, can improve health measures and quality of life in women who have polycystic ovary syndrome (PCOS) and are overweight or have obesity. you would be assigned by chance (like flipping a coin) to receive either the synbiotic supplement or a dummy treatment (placebo) (a look-alike product with no active ingredients).

NCT07342946 · Official ClinicalTrials.gov record · Atlas University

RecruitingNot a traditional drug phaseBordeaux
Multicenter Prospective Cohort on Esophageal Endoscopic Submucosal Dissection

In France in 2018, there were an estimated 2,074 new cases of esophageal adenocarcinoma and 3,224 cases of squamous cell carcinoma. The estimated deaths from esophageal cancer were 3,725, with a standardized 5-year net survival rate of 20% for cases diagnosed between 2010 and 2015, mainly due to late diagnosis.

NCT07343869 · Official ClinicalTrials.gov record · Société Française d'Endoscopie Digestive

RecruitingNot a traditional drug phaseOslo
Not a traditional drug phase: Transdiagnostic app intervention for Major Depression Disorder

Some adolescents experience periods of anxiety and/or depression, and some find that these periods return over time. this study wants to examine whether digital interventions-where individuals work systematically with their own thoughts and feelings during periods when they feel well-can help them maintain well-being for longer.

NCT07346911 · Official ClinicalTrials.gov record · University of Oslo

RecruitingNot a traditional drug phaseSalamanca
Not a traditional drug phase: testing Empagliflozin for Chronic Kidney Disease

This prospective watch-and-measure (no experimental treatment required) study aims to assess the association between real-world use of sodium-glucose co-transporter 2 inhibitors (SGLT2i; e.g., empagliflozin, dapagliflozin) and renal function decline in adults with chronic kidney disease (CKD) stages 2-4 (KDIGO classification). The study will also validate a urinary biomarker panel for early diagnosis and monitoring of CKD progression.

NCT07348484 · Official ClinicalTrials.gov record · Instituto de Investigación Biomédica de Salamanca

RecruitingNot a traditional drug phaseGuangzhou, Guangdong
Not a traditional drug phase: testing Ofatumumab for Multiple Sclerosis

Multiple sclerosis (MS) is an immune-mediated disease characterized primarily by inflammatory demyelinating lesions in the central nervous system (CNS), with the white matter being predominantly affected. Its etiology remains unclear and may be associated with various factors such as genetics, environment, and viral infections .

NCT07353216 · Official ClinicalTrials.gov record · Third Affiliated Hospital, Sun Yat-Sen University

RecruitingPhase 4Seongnam
Phase 4: testing Faricimab Injection [Vabysmo] for Macular Degeneration

If the subject who has nAMD voluntarily agrees to participate in this clinical study by signing the informed consent form, screening assessments will be conducted within 4 weeks prior to the first dose of the investigational drug. During the screening visit, the eligibility of the subject will be assessed and one study eye will be selected.

NCT07367282 · Official ClinicalTrials.gov record · Junyeop Lee

RecruitingNot a traditional drug phaseCaen
Not a traditional drug phase: Questionnaires for Multiple Sclerosis

Multiple sclerosis (MS), an inflammatory, neurodegenerative disease of the central nervous system, affects around 120,000 patients in France and is the leading cause of non-traumatic disability in young adults. It affects patients' health-related quality of life (QoL) and has a significant economic impact on patients and society as a whole.

NCT07372599 · Official ClinicalTrials.gov record · University Hospital, Caen

RecruitingEarly phase 1Waltham, Massachusetts
Early phase 1: Virtual Reality for Persistent Postural Perceptual Dizziness

Both persistent postural-perceptual dizziness (PPPD) and vestibular migraine (VM) are common diagnoses in patients presenting to physicians for evaluation of vestibular symptoms such as dizziness and vertigo. Although they are most often described in the adult population, they are also common in children and adolescents with dizziness.

NCT07374640 · Official ClinicalTrials.gov record · Boston Children's Hospital

RecruitingNot a traditional drug phaseKigali
Not a traditional drug phase: Thermal ablation (TA) with 1 probe for HIV (Human Immunodeficiency Virus)

Cervical cancer disproportionately affects women in low- and middle-income countries (LMICs), particularly women living with HIV (WLWH) who have a 6-fold increased risk of cervical cancer compared to women in the general population. Thermal ablation (TA) is recommended by the World Health Organization (WHO) to treat cervical precancerous lesions, although its how well it works can be suboptimal in WLWH.

NCT07390916 · Official ClinicalTrials.gov record · Fred Hutchinson Cancer Center

RecruitingNot a traditional drug phaseNew Delhi, National Capital Territory of Delhi
Not a traditional drug phase: testing Semaglutide Oral Tablet for Chronic Kidney Diseases

This project aims to investigate how Chronic Kidney Disease (CKD) develops and progresses in patients who also have Non-Alcoholic Fatty Liver Disease (NAFLD) and to evaluate whether oral semaglutide (a GLP-1 receptor agonist) can slow or prevent this progression. NAFLD and CKD frequently coexist due to shared mechanisms such as insulin resistance, inflammation, oxidative stress, dyslipidemia, and metabolic syndrome.

NCT07391267 · Official ClinicalTrials.gov record · Institute of Liver and Biliary Sciences, India

RecruitingPhase 3Phoenix, Arizona
Phase 3: testing Linvoseltamab for High Risk Smoldering Multiple Myeloma (HR-SMM)

This study is researching an experimental drug called linvoseltamab (also called "study drug") compared to another drug called daratumumab, in participants with Smoldering Multiple Myeloma (SMM), who are at a High Risk (HR) of developing active multiple myeloma. The aim of this study is to find out whether linvoseltamab is better than daratumumab in delaying the development of MM.

NCT07393282 · Official ClinicalTrials.gov record · Regeneron Pharmaceuticals

RecruitingNot a traditional drug phaseLleida, Catalonia
Not a traditional drug phase: Interdisciplinary intervention for COPD - Chronic Obstructive Pulmonary Disease

Introduction: Pulmonary rehabilitation programs (PRPs) are known to reduce symptoms such as dyspnea and fatigue, while improving functional capacity and quality of life in individuals with chronic obstructive pulmonary disease (COPD). However, the benefits of an initial pulmonary rehabilitation program (PRP) tend to diminish rapidly over time, prompting the development of strategies to maintain these effects.

NCT07394712 · Official ClinicalTrials.gov record · Institut de Recerca Biomèdica de Lleida

RecruitingNot a traditional drug phaseCharleston, South Carolina
Not a traditional drug phase: Accelerated intermittent theta-burst stimulation (iTBS) rTMS to left dorsomedial prefrontal cortex (dmPFC) for Parkinson Disease

This single-site, open-label pilot study will measure the feasibility, tolerability, and preliminary how well it works of accelerated intermittent theta-burst stimulation (iTBS) targeting the dorsomedial prefrontal cortex (dmPFC) for apathy in individuals with Parkinson's Disease (PD). Fifteen participants with PD and clinically significant apathy will undergo imaging (EEG and MRI) and one day of TMS including twelve iTBS sessions across two visits.

NCT07399496 · Official ClinicalTrials.gov record · Medical University of South Carolina

RecruitingNot a traditional drug phasePrague
Not a traditional drug phase: Right Greater Splanchnic Nerve (GSN) ablation for Heart Failure With Reduced Ejection Fraction (HFrEF)

This study is a small, early-stage clinical trial designed to test whether a new catheter-based procedure is safe and may help people with heart failure with reduced ejection fraction (HFrEF). The procedure uses the Satera Ablation System to treat the right greater splanchnic nerve, which may play a role in heart failure symptoms.

NCT07403058 · Official ClinicalTrials.gov record · Axon Therapies, Inc.

RecruitingPhase 2Toronto, Ontario
Phase 2: testing Psilocybin 25 mg for Major Depressive Disorder (MDD)

The goal of this clinical trial is to determine the safety and how well it works of psilocybin assisted Therapy (PAT) in individuals with comorbid Major Depressive Disorder (major depression) and Alcohol Use Disorder (AUD). The main question it aims to answer is: \- What is the feasibility and safety of administering PAT in adults with major depression-AUD by evaluating recruitment, retention, tolerability, and safety?

NCT07405606 · Official ClinicalTrials.gov record · Centre for Addiction and Mental Health

RecruitingNot a traditional drug phaseChicago, Illinois
Not a traditional drug phase: Eye Tracker for Spinal Cord Injury

Many individuals with severe motor impairments rely on Assistive Technologies (ATs) or Brain-Computer Interfaces (BCIs) to interact with digital devices such as their computers. Clinicians and researchers currently lack a common framework to objectively quantify how much a given AT or BCI improves real-world function or to compare across tools.

NCT07407725 · Official ClinicalTrials.gov record · Shirley Ryan AbilityLab

RecruitingEarly phase 1Evanston, Illinois
Early phase 1: Dream Yoga Inspired Intervention for Anxiety

People spend approximately one-third of their lives asleep, yet sleep is often underused as an opportunity to support psychological well-being. Contemplative traditions, including Tibetan Dream Yoga, have developed practices that use waking imagination and lucid dreaming to explore perception, awareness, and habitual patterns of thinking.

NCT07408206 · Official ClinicalTrials.gov record · Northwestern University

RecruitingNot a traditional drug phaseAntalya, Antalya
Not a traditional drug phase: Exercise Program for Ankle Osteoarthritis

The aim of our study is to measure the effects of graded motor imagery training applied in addition to a structured exercise program in individuals with foot and/or ankle osteoarthritis. The study population will consist of twenty-four individuals diagnosed with foot/ankle osteoarthritis who applied to the Orthopedics and Traumatology Department of Alanya Alaaddin Keykubat University Education and Research Hospital.

NCT07417436 · Official ClinicalTrials.gov record · Alanya Alaaddin Keykubat University

RecruitingNot a traditional drug phaseChicago, Illinois
Outpatient Visits Versus Telehealth for Postoperative Care After Minimally Invasive Gynecologic Surgery

Telehealth, or telemedicine, utilizes technology to deliver clinical care remotely, either in real time or asynchronously, between clinician and patient. Telemedicine has been successfully implemented to increase healthcare delivery for patients in rural areas with otherwise long travel times, and studies have also determined that telemedicine can increase patient satisfaction scores while simultaneously decreasing direct and indirect costs for patients.

NCT07420114 · Official ClinicalTrials.gov record · University of Chicago

RecruitingPhase 3Anniston, Alabama
Phase 3: testing Anifrolumab for Systemic Lupus Erythematosus

The purpose of the SUNFLOWER study is to describe clinical outcomes, including DORIS remission, achieved following the initiation of anifrolumab 120 mg SC once weekly (QW) as add-on therapy to an anti-malarial, with or without GC; in patients not in LLDAS at enrolment. Patients will be naïve to any prior conventional immunosuppressant including prior biologic therapy at enrolment.

NCT07430306 · Official ClinicalTrials.gov record · AstraZeneca

RecruitingNot a traditional drug phaseNairobi
Not a traditional drug phase: Thermal ablation (TA) with 1 probe for HIV (Human Immunodeficiency Virus)

Cervical cancer disproportionately affects women in low- and middle-income countries (LMICs), particularly women living with HIV (WLWH) who have a 6-fold increased risk of cervical cancer compared to women in the general population. Thermal ablation (TA) is recommended by the World Health Organization (WHO) to treat cervical precancerous lesions, although its how well it works can be suboptimal in WLWH.

NCT07468695 · Official ClinicalTrials.gov record · Fred Hutchinson Cancer Center

RecruitingNot a traditional drug phaseOxford
Not a traditional drug phase: There are no interventions for this study for Pre-eclampsia

Pre-eclampsia (PET) is a condition characterised by high blood pressure and damage to other organs, and is a leading cause of maternal and fetal complications such as fetal growth restriction (FGR). Gestational diabetes mellitus (GDM) involves abnormal blood sugar levels during pregnancy and can have both short and long-term impacts on the health of the mother and child.

NCT07470320 · Official ClinicalTrials.gov record · University of Oxford

RecruitingNot a traditional drug phaseHong Kong
Not a traditional drug phase: Chatbot-delivered online interventions and online videos for Behavior

The goal of this clinical trial is to see if receiving chatbot-delivered stage-of-change-tailored online interventions is effective in reducing chemsex among men who have sex with men in Hong Kong. The main question it aims to answer is: Does chatbot-delivered stage-of-changed online interventions reduce chemsex among men who have sex with men Eligible you would be randomly assigned to either the intervention or the control group.

NCT07472582 · Official ClinicalTrials.gov record · Chinese University of Hong Kong

RecruitingNot a traditional drug phaseEdinburgh
Not a traditional drug phase: testing Bisoprolol for Takotsubo Cardiomyopathy

The goal of this research study is to further understand the physiological mechanisms involved in a heart condition called takotsubo cardiomyopathy, also known as broken heart syndrome. Furthermore, the investigators will be assessing the effects different cardiac medications have on these physiological mechanisms.

NCT07491718 · Official ClinicalTrials.gov record · University of Edinburgh

RecruitingNot a traditional drug phaseManaus, Amazonas
Not a traditional drug phase: testing Lenacapavir long-acting for Contact With or Exposure to Human Immunodeficiency Virus

The goal of this study is to learn how well long-acting lenacapavir works to prevent human immunodeficiency virus (HIV) infection in people at higher risk of getting HIV in Brazil. The study will also learn about safety, continued use over time, and whether people prefer this option compared to daily oral pre- exposure prophylaxis (PrEP).

NCT07497594 · Official ClinicalTrials.gov record · Oswaldo Cruz Foundation

RecruitingPhase 2Fayetteville, Arkansas
Phase 2: testing Anti-VEGF Monoclonal Antibody for Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma

This phase II trial compares the effect of sacituzumab govitecan and bevacizumab to standard care (carboplatin, pegylated liposomal doxorubicin, and bevacizumab) in patients with ovarian cancer that has come back after an initial response to platinum therapy (platinum-sensitive), that has progressed after poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitor maintenance therapy (recurrent), and that has a mutation in the BRCA1 or BRCA2 genes or is homologous recombination deficient. Sacituzumab govitecan is a monoclonal antibody, called sacituzumab, linked to a drug called govitecan.

NCT07504588 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)

RecruitingNot a traditional drug phaseTainan, Taiwan
Not a traditional drug phase: Brief Behavioral Therapy for Insomnia (BBTi) for Comorbid Insomnia and Sleep Apnea

This study investigates the how well it works of a wearable voice-guided Brief Behavioral Therapy for Insomnia (BBTi) combined with a smart eye-mask device for individuals with Comorbid Insomnia and Sleep Apnea (COMISA). The four-year study comprises three phases: (1) exploration of cognitive-emotion regulation-arousal system mechanisms in COMISA and pilot BBTi intervention testing, (2) development and usability testing of an integrated smart eye-mask with BBTi voice-guided modules, and (3) a multi-center randomly assigned controlled trial (RCT) evaluating the combined BBTi plus smart eye-mask intervention versus BBTi alone, smart eye-mask alone, and standard sleep hygiene education in 160 COMISA participants.

NCT07521319 · Official ClinicalTrials.gov record · National Sun Yat-sen University

RecruitingNot a traditional drug phaseBaltimore, Maryland
Not a traditional drug phase: INTENT Neural Interface System for Tetraplegia/Tetraparesis

The goal of this clinical trial is to measure the safety and preliminary how well it works of an implantable device that records and stimulates different areas of the brain to allow adults affected by disabling paralysis (see Eligibility for more details) to control and receive feedback from assistive devices.

NCT07521930 · Official ClinicalTrials.gov record · Johns Hopkins University

RecruitingNot a traditional drug phaseBirmingham, Alabama
Not a traditional drug phase: VARIPULSE Catheter System for Atrial Fibrillation

This study wants to assess how safe VARIPULSE catheter system is for treatment of a heart rhythm disease called persistent atrial fibrillation (PsAF) in participants who are having a catheter ablation procedure (treat heart rhythm disease). This includes isolation of pulmonary vein and superior vena cava (heart veins; pulmonary vein isolation \[PVI\] and superior vena cava isolation \[SVCI\]), with or without another technique called posterior wall isolation (PWI).

NCT07527299 · Official ClinicalTrials.gov record · Biosense Webster, Inc.

RecruitingPhase 2Tucson, Arizona
Phase 2: testing ALN-PNP for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

This study will test a study drug called ALN-PNP with and without another drug that is used for controlling blood sugar, appetite, and weight (for example, tirzepatide), to see if it can help treat MASLD, also known as fatty liver disease. ALN-PNP reduces the amount of Patatin-like phospholipase domain-containing protein 3 (PNPLA3), a protein that liver cells make, which may help decrease liver fat if there is an abnormal PNPLA3 protein.

NCT07527910 · Official ClinicalTrials.gov record · Regeneron Pharmaceuticals

RecruitingNot a traditional drug phaseAtlanta, Georgia
Not a traditional drug phase: Virtual Peer Recovery Coaching for Substance Use

The goal of this study is to learn whether a virtual peer recovery coach (PRC) intervention can improve engagement in addiction treatment among incarcerated adults with substance use disorders. The main questions it aims to answer are: * Does the PRC intervention increase engagement with at least one recovery resource at 30 and 90 days?

NCT07563517 · Official ClinicalTrials.gov record · Emory University

RecruitingNot a traditional drug phaseBoston, Massachusetts
Not a traditional drug phase: Psychedelic Integration Coaching for Treatment Resistant Depression (TRD)

This study is being conducted at Massachusetts General Hospital (MGH) to explore whether adding psychedelic coaching can enhance the effects of ketamine or esketamine maintenance treatment in individuals with treatment-resistant depression (TRD). The investigators are currently enrolling participants who are receiving ongoing maintenance intravenous (IV) ketamine or intranasal esketamine (Spravato) treatment at the MGH Ketamine Clinic.

NCT07563868 · Official ClinicalTrials.gov record · Massachusetts General Hospital

RecruitingPhase 2Toronto, Ontario
Phase 2: testing Ketamine Hydrochloride for Borderline Personality Disorder (BPD)

The goal of this clinical trial is to learn if intravenous (IV) ketamine with Dialectical Behavioural Therapy (DBT) reduces suicidal ideation in individuals with suicidality who have been diagnosed with Borderline Personality Disorder and either Major Depressive Disorder or Bipolar Disorder. The main question it aims to answer is: Does IV ketamine and DBT produce more rapid and robust improvements in suicidal ideation (SI) severity between baseline and Day 35 compared to IV midazolam and DBT, as measured by changes in the Modified Scale for Suicidal Ideation (MSSI) scores ?

NCT07569198 · Official ClinicalTrials.gov record · Joshua Rosenblat

RecruitingNot a traditional drug phaseShanghai, Shanghai Municipality
Not a traditional drug phase: No study-specific intervention for Alzheimer's Disease(AD)

The goal of this prospective, multicenter, watch-and-measure (no experimental treatment required) cohort study is to measure the screening performance of blood-based biomarkers for Alzheimer's disease (AD) in a real-world community screening setting, and to establish the population baseline levels and reference intervals of these biomarkers in Chinese older adults. The main questions it aims to answer is: What is the clinical screening value of blood biomarkers (phosphorylated tau 217 to amyloid β 42 ratio \[pTau217/Aβ42\] and glial fibrillary acidic protein \[GFAP\]) for AD among community-dwelling older adults?

NCT07570719 · Official ClinicalTrials.gov record · Kuang XiaoJun

RecruitingPhase 1Leuven
Phase 1: testing LY4256984 for Amyotrophic Lateral Sclerosis

The main purpose of this study is to assess the long-term whether it is safe and how hard side effects are to live with of LY4256984 in participants with Amyotrophic Lateral Sclerosis (ALS). This study is a long-term extension of study J6I-MC-OWAA (NCT07100119) and is part of the OLMP (NCT07571200) master protocol that will last approximately 96 weeks.

NCT07571174 · Official ClinicalTrials.gov record · Eli Lilly and Company

RecruitingPhase 4Daegu, Daegu
Phase 4: testing Sacubitril / Valsartan for Heart Failure Due to Coronary Artery Disease

In patients with heart failure due to a reversible underlying cause-such as valvular heart disease or coronary artery disease-surgical or procedural correction of the underlying lesion (valve repair/replacement, TAVI, PCI, or CABG) frequently leads to spontaneous recovery of cardiac function, even without neurohormonal modulators. In this clinical setting, a substantial proportion of patients may not require the full set of guideline-directed medical therapies routinely prescribed for chronic HFrEF.

NCT07572032 · Official ClinicalTrials.gov record · Kyungsub Song

RecruitingNot a traditional drug phaseKuwait City
Not a traditional drug phase: testing Tirzepatide (Per-label titration) for Obesity

The goal of this clinical trial is to determine whether a flexible, symptom-guided titration strategy for tirzepatide can help adults with obesity without diabetes stay on treatment longer, while maintaining weight-loss effectiveness. The main questions it aims to answer are: * Does flexible, symptom-guided titration increase time on treatment (delay treatment discontinuation) compared with standard per-label titration over 76 weeks?

NCT07574723 · Official ClinicalTrials.gov record · Dasman Diabetes Institute

RecruitingNot a traditional drug phasePoznan
Not a traditional drug phase: testing Intrathecal Morphine for Arthropathy of Hip

The goal of this clinical trial is to learn which of three regional anesthesia approaches provides better pain relief and safety for older adults having planned hip replacement surgery. Researchers will study people aged 60 years and older who are scheduled for elective total hip arthroplasty.

NCT07584200 · Official ClinicalTrials.gov record · Poznan University of Medical Sciences

RecruitingPhase 2La Jolla, California
Phase 2: EEG Neurofeedback for SCHIZOPHRENIA 1 (Disorder)

This study is a confirmatory, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment randomly assigned clinical trial (RCT) testing whether gamma EEG neurofeedback (EEG-NFB) improves working memory in adults with schizophrenia or schizoaffective disorder. Participants are randomly assigned to receive either active gamma EEG-NFB (real-time feedback of frontal gamma brain activity) or sham EEG-NFB (false pre-recorded feedback), twice weekly for 12 weeks.

NCT07592169 · Official ClinicalTrials.gov record · University of California, San Diego

RecruitingNot a traditional drug phaseParis
Not a traditional drug phase: HEMI device for Chronic Kidney Disease

This prospective, single-center clinical investigation conducted in France will evaluate two non-invasive investigational devices (HEMI and SPG-NINOX) designed to assess microcirculation in adults. The study will include 165 participants divided into five groups (33 per group): healthy volunteers, patients with hypertension without chronic kidney disease (CKD), patients with type 2 diabetes without CKD, patients with moderate CKD, and patients with severe CKD.

NCT07604922 · Official ClinicalTrials.gov record · Institut National de la Santé Et de la Recherche Médicale, France

RecruitingNot a traditional drug phaseBoston, Massachusetts
Not a traditional drug phase: Miracle of Mind meditation for Mental Health and General Well-being

This study is testing whether a short, daily, app-based meditation can help young adults feel better in their everyday lives. Adults aged 18-40 years who live in the United States and have not meditated regularly (defined as more than four times per week at any point in their lives) are invited to participate.

NCT07607782 · Official ClinicalTrials.gov record · Beth Israel Deaconess Medical Center

RecruitingPhase 3Huntsville, Alabama
Phase 3: testing Balcinrenone/dapagliflozin for Renal Insufficiency, Chronic

This study wants to measure the how well it works, whether it is safe and how hard side effects are to live with of balcinrenone in fixed combination with dapagliflozin, compared with dapagliflozin, in patients with CKD Stage 3b and 4 (eGFR ≥ 15 to \< 45 mL/min/1.73 m2) administered orally once daily in addition to SoC. This is a population with high unmet medical need and an increased risk of CKD progression, who are frequently excluded from treatment trials.

NCT07624305 · Official ClinicalTrials.gov record · AstraZeneca

RecruitingNot a traditional drug phaseAurora, Colorado
Not a traditional drug phase: Group Self-Management Sessions for Brain Cancer

The goal of this clinical trial is to learn if the newly designed group self-management program is feasible to conduct and improves mental and behavioral health outcomes compared to a control group in people diagnosed with brain cancer. The main questions it aims to answer are: * Is it feasible to conduct this program?

NCT07628647 · Official ClinicalTrials.gov record · University of Colorado, Denver

RecruitingPhase 4Daegu, Daegu
Phase 4: testing Stepwise Withdrawal of ARNI and SGLT2i for Heart Failure With Reduced Ejection Fraction

This is a multicenter, randomly assigned, open-label pilot study to evaluate whether stepwise withdrawal of two heart failure medications-angiotensin receptor-neprilysin inhibitor (ARNI) and sodium-glucose cotransporter-2 inhibitor (SGLT2i)-is safe in patients with Heart Failure with improved Ejection Fraction (HFimpEF) whose underlying structural cause (valvular heart disease or ischemic cardiomyopathy) has been completely corrected by surgery or intervention. Eighty adult patients (40 per arm) whose left ventricular ejection fraction (LVEF) has recovered to 50% or higher and whose NT-proBNP is ≤ 250 ng/L will be randomly assigned 1:1 to either (1) stepwise withdrawal of ARNI followed by SGLT2i over one month under close echocardiographic monitoring, or (2) continuation of their current guideline-directed medical therapy.

NCT07631156 · Official ClinicalTrials.gov record · Kyungsub Song

RecruitingPhase 1 / Phase 2Scottsdale, Arizona
Phase 1 / Phase 2: testing VMD-102 for Hepatocellular Carcinoma (HCC)

This study is to measure the whether it is safe and how hard side effects are to live with to determine (i) the recommended Phase 2 dose (RP2D) of VMD-102 (Phase 1), and (ii) preliminary anti-tumor how well it works (Phase 2), in participants with advanced HCC, metastatic uveal melanoma (MUM), renal cell carcinoma (RCC), non-small cell lung cancer (NSCLC), and colorectal cancer (CRC). The pharmacokinetics (PK), preliminary anti-tumor activity, and potential biomarkers of VMD-102 will also be assessed.

NCT07636785 · Official ClinicalTrials.gov record · VM Discovery, Inc.

RecruitingNot a traditional drug phaseAnn Arbor, Michigan
Striatal and Extra-Striatal Cholinergic Terminal Density in LRRK2-PD Mutation

This study explores how a specific genetic mutation of leucine-rich repeat kinase 2 (LRRK2) affects individuals with Parkinson's disease (PD), comparing those with the mutation to others with Parkinson's disease and without the mutation (iPD). Participants will complete positron emission tomography (PET) and magnetic resonance imaging (MRI) brain imaging, cognitive tests, motor tests, sensory tests, and questionnaires.

NCT07642908 · Official ClinicalTrials.gov record · University of Michigan

RecruitingNot a traditional drug phaseTel Aviv
Not a traditional drug phase: This is an observational study with no intervention. Patients will receive anti- TNF therapy as part of their standard care for IBD (Inflammatory Bowel Disease)

This watch-and-measure (no experimental treatment required) study aims to identify genes that may affect how patients with inflammatory bowel disease respond to anti-TNF treatment and why some patients lose response to treatment over time. The study will examine whether genetic markers can help predict which patients are more likely to respond to anti-TNF therapy.

NCT07644117 · Official ClinicalTrials.gov record · Shmuel Kivity, MD

RecruitingNot a traditional drug phaseHarare
Not a traditional drug phase: Thermal ablation (TA) with 1 probe for HIV (Human Immunodeficiency Virus)

Cervical cancer disproportionately affects women in low- and middle-income countries (LMICs), particularly women living with HIV (WLWH) who have a 6-fold increased risk of cervical cancer compared to women in the general population. While thermal ablation (TA) is a WHO- recommended treatment for cervical precancerous lesions, its how well it works can be suboptimal in WLWH.

NCT07645352 · Official ClinicalTrials.gov record · Fred Hutchinson Cancer Center

RecruitingPhase 1Rockville, Maryland
Phase 1: testing Cyclophosphamide for AIDS-Related Diffuse Large B-cell Lymphoma

This phase I trial studies the safety and side effects of glofitamab plus a chemoimmunotherapy regimen called R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) in treating patients newly-diagnosed with HIV-associated large B-cell lymphoma. Glofitamab is a bispecific monoclonal antibody, which can bind to two different antigens that are expressed by cancer cells (CD3 and CD20) at the same time.

NCT07649304 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)

RecruitingNot a traditional drug phaseDelray Beach, Florida
Not a traditional drug phase: BodyGuardian for Atrial Fibrillation (AF)

The DISRUPT-AF Registry is an watch-and-measure (no experimental treatment required), prospective, multi-center, non-randomly assigned, real-world registry designed to obtain clinical experience with the FARAPULSE Pulsed Field Ablation (PFA) System for the treatment of atrial fibrillation (AF). The data collected for this study will be from a subset of patients enrolled in the pre-existing DISRUPT AF Registry.

NCT07671677 · Official ClinicalTrials.gov record · Heart Rhythm Clinical and Research Solutions, LLC

RecruitingNot a traditional drug phaseBaltimore, Maryland
Not a traditional drug phase: Sham 2D Headset Control for Sickle Cell Disease

This randomly assigned pilot study will measure the feasibility, tolerability, and preliminary analgesic effect of headset-based virtual reality (VR) interventions for adults with sickle cell disease (SCD) experiencing vaso-occlusive crisis (VOC) treated in an infusion center. Up to 50 you would be enrolled, provide informed consent, and undergo randomization during routine outpatient sickle cell clinic visits when they are clinically stable and not experiencing an acute VOC.

NCT07674277 · Official ClinicalTrials.gov record · University of Maryland, Baltimore

RecruitingPhase 1 / Phase 2Lübeck, Schleswig-Holstein
Phase 1 / Phase 2: testing TRCN-1023 for Amyotrophic Lateral Sclerosis

The FUNCtion Amyotrophic Lateral Sclerosis (ALS) trial is a randomly assigned, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment Phase 1/2 trial to measure the whether it is safe and how hard side effects are to live with of TRCN-1023 in adults living with ALS. TRCN-1023 is an investigational medicine given as a single injection into the fluid surrounding the spine (intrathecal injection).

NCT07674667 · Official ClinicalTrials.gov record · Trace Neuroscience, Inc.

RecruitingNot a traditional drug phaseBadalona, Barcelona
A Study to Estimate Secukinumab Retention Rate in Psoriasis Patients With MASLD

This study aims to examine the retention rate of secukinumab in adult patients with plaque psoriasis (with or without psoriatic arthritis \[PsA\]) and metabolic dysfunction-associated steatotic liver disease (MASLD) in routine clinical practice in Spain, as well as hepatic biomarker trajectories. The study will use electronic medical record (EMR) data from multiple Spanish hospitals.

NCT07683065 · Official ClinicalTrials.gov record · Novartis Pharmaceuticals

RecruitingPhase 3Toronto, Ontario
Phase 3: testing Mocertatug rezetecan for Neoplasms, Endometrial

This study wants to see how well mocertatug rezetecan (Mo-Rez) in combination with physician's choice of immunotherapy (dostarlimab or pembrolizumab) works as maintenance therapy in participants with advanced or recurrent endometrial cancer (EC) compared with the physician's choice of immunotherapy (dostarlimab or pembrolizumab) alone, which represents the current standard of care. The study will also assess whether the drug combination is safe and tolerated well by participants compared to standard of care and will help us better understand its impact on Health-Related Quality of Life of participants.

NCT07684599 · Official ClinicalTrials.gov record · GlaxoSmithKline

RecruitingPhase 4Hefei, Anhui
Phase 4: testing Tirzepatide for Obesity

This multicenter randomly assigned controlled trial will evaluate whether an AI-assisted intensive lifestyle intervention can improve weight and glycemic management in adults with obesity and newly diagnosed type 2 diabetes, compared with tirzepatide treatment and standard lifestyle management. Eligible you would be adults aged 18 to 65 years with a body mass index of 28 to less than 40 kg/m² and newly diagnosed type 2 diabetes who have not used glucose-lowering medications in the past 3 months.

NCT07697391 · Official ClinicalTrials.gov record · The First Affiliated Hospital of Anhui Medical University

RecruitingNot a traditional drug phaseOsmaniye, Osmaniye
Not a traditional drug phase: 4-7-8 Breathing Technique for Diabetic Neuropathies

This study aims to determine the effect of the 4-7-8 breathing technique, applied during Electromyography (EMG) for the diagnosis of diabetic peripheral neuropathy, on the pain and anxiety levels experienced by patients with Type 2 diabetes. EMG is a diagnostic method that can cause pain and anxiety in patients.

NCT07702175 · Official ClinicalTrials.gov record · Nurgül Gün

RecruitingNot a traditional drug phaseHualien City, Hualien County
Not a traditional drug phase: Enhanced Recovery After Surgery (ERAS) pathway for Preoperative Anxiety

This study investigates whether an Enhanced Recovery After Surgery (ERAS) program can help orthopedic surgery patients feel less anxious before their operation and recover better one year after surgery, compared to conventional (standard) surgical care. Patients who undergo orthopedic surgery, such as joint replacement, often experience significant anxiety before the operation.

NCT07706244 · Official ClinicalTrials.gov record · Buddhist Tzu Chi General Hospital

RecruitingNot a traditional drug phaseDoorn, Utrecht
Working Mechanisms and Effectiveness of IV Ketamine-assisted Psychotherapy on Depression in TRD Clients

Ketamine-Assisted Psychotherapy (KAP) is an innovative treatment that combines intravenous ketamine with psychotherapy in a carefully monitored clinical setting. At Senz, this treatment is being evaluated in an open-label clinical trial for individuals with persistent depression who have not responded sufficiently to previous treatments.

NCT07706478 · Official ClinicalTrials.gov record · Senz

RecruitingNot a traditional drug phaseSan Antonio, Texas
Not a traditional drug phase: Live workshop for PTSD - Post Traumatic Stress Disorder

This research study tests strategies to train behavioral health providers in Written Exposure Therapy (WET), an evidence-based treatment for posttraumatic stress disorder (PTSD). There are a number of evidence-based treatments for posttraumatic stress disorder (PTSD).

NCT07707102 · Official ClinicalTrials.gov record · The University of Texas Health Science Center at San Antonio

RecruitingPhase 1Boston, Massachusetts
Phase 1: testing autologous bone marrow derived CD34+ HSPCs electroporated with BCL11A enhancer targeting Cas9 ribonucleoprotein for Sickle Cell Disease

A promising approach for the treatment of genetic diseases is called gene therapy. Gene therapy is a relatively new field of medicine that uses genetic material (mostly deoxyribonucleic acid (DNA)) from the patient to treat his or her own disease.

NCT07708350 · Official ClinicalTrials.gov record · Daniel Bauer

RecruitingPhase 4Ottawa, Ontario
Phase 4: testing Methylphenidate hydrochloride extended-release capsules for Attention Deficit Hyperactivity Disorder

This study is evaluating the safety and effectiveness of Foquest (multilayer-release methylphenidate), a once-daily extended-release medication for attention-deficit/hyperactivity disorder (ADHD), in adults aged 65 years and older. ADHD can persist into older age and is associated with reduced quality of life and difficulties with executive function.

NCT07710014 · Official ClinicalTrials.gov record · Dar Clinical Research Inc.

RecruitingNot a traditional drug phaseChicago, Illinois
Not a traditional drug phase: testing Ocrevus Zunovo for Multiple Sclerosis

Ocrevus Zunovo implementation, feasibility, acceptability, patient satisfaction, treatment persistence, and impact on MS disease outcomes will be analyzed in this mixed methods study. This study will incorporate clinical data and questionnaire results from MS patients who take Ocrevus Zunovo as well as qualitative interviews with MS patients, family members, and other individuals involved in Ocrevus Zunovo treatment.

NCT07710105 · Official ClinicalTrials.gov record · Northwestern University

RecruitingPhase 3Redlands, California
Phase 3: testing Esketamine 56 mg for Depressive Disorder, Treatment-Resistant

This study wants to evaluate how well each individual dose of esketamine (56 milligrams \[mg\] and 84 mg) works when compared with dummy treatment (placebo) in improving depressive symptoms in participants with treatment resistant depression (individuals with major depressive disorder \[major depression\] who have not responded to at least 2 different antidepressant treatments given at an adequate dose for an adequate duration in the current episode of depression).

NCT07716098 · Official ClinicalTrials.gov record · Janssen Research & Development, LLC

RecruitingPhase 2Hefei, Anhui
Phase 2: testing SMP-656 Injection for HER2-positive Breast Cancer

The goal of this clinical trial is to learn if single-agent SMP-656 works to treat patients with HER2-positive locally advanced or metastatic breast cancer who have progressed after prior HER2-targeted topoisomerase inhibitor antibody-drug conjugate (ADC) treatment. It will also measure the safety of SMP-656 and identify the optimal dose for future trials.

NCT07726342 · Official ClinicalTrials.gov record · Chengdu SciMount Pharmatech Co., Ltd.

RecruitingNot a traditional drug phaseMadison, Wisconsin
Not a traditional drug phase: MRI Visit for PCOS

This study wants to determine how polycystic ovary syndrome (PCOS) impacts overall brain health, such as cerebral blood flow (CBF), brain structure and connectivity, and cognitive performance. 45 reproductive aged (18-45 years) individuals with ovaries, with and without PCOS, will be enrolled to complete brain structure and CBF scans via magnetic resonance imaging (MRI) over 2 testing visits and can expect to be on study for approximately 5 hours over a 1 to 3 month period.

NCT07727512 · Official ClinicalTrials.gov record · University of Wisconsin, Madison

RecruitingNot a traditional drug phaseLeeds
Not a traditional drug phase: testing Tezepelumab for Severe Asthma

This study will see if a structured physical activity promotion programme, delivered alongside standard treatment with tezepelumab, increases objectively measured physical activity and the proportion of adults with severe asthma achieving clinical remission compared with standard care alone. Although biologic therapies have improved asthma control for many people with severe asthma, many individuals remain physically inactive, experience reduced exercise tolerance, and continue to report symptoms that affect their quality of life.

NCT07735494 · Official ClinicalTrials.gov record · University of Leeds

RecruitingNot a traditional drug phaseLebanon, New Hampshire
Not a traditional drug phase: HOBSCOTCH/HOBSCOTCH-YOUTH for Epilepsy

The goal of this clinical trial is to learn more about the home-based epilepsy self-management program, HOBSCOTCH, for improving cognitive function (thinking and memory) and quality of life specifically in young adults, ages 18 - 29 years, who have epilepsy. It will also learn if a modification of the program for youth with epilepsy, ages 13 - 17, improves thinking and memory and quality of life and reduces stress for their parents.

NCT07735715 · Official ClinicalTrials.gov record · Dartmouth-Hitchcock Medical Center

RecruitingNot a traditional drug phaseNew York, New York
Not a traditional drug phase: Medtronic Percept PC DBS system for Bipolar I Disorder

This study addresses a critical unmet need in the treatment of bipolar disorder by investigating whether Subcallosal Cingulate (SCC) Deep Brain Stimulation (DBS) can safely and effectively treat treatment-resistant bipolar depression without inducing manic switches. The researchers propose to accomplish this by incorporating monitoring of the SCC local field potentials (LFP) for depression tracking and amygdala LFP monitoring for mania prediction while treating Bipolar I patients with SCC DBS Stimulation.

NCT07745374 · Official ClinicalTrials.gov record · Icahn School of Medicine at Mount Sinai

RecruitingNot a traditional drug phaseSantiago, Santiago Metropolitan
Not a traditional drug phase: Expectancy Focused Exposure for Anxiety Disorders

This clinical trial evaluates whether an optimized exposure-based treatment improves long-term outcomes for adults with anxiety disorders. Specifically, it examines whether Expectancy Focused Exposure (EFE), based on the inhibitory learning model, is more effective than Anxiety Focused Exposure (AFE) in reducing anxiety symptoms and preventing the return of fear over time.

NCT07753330 · Official ClinicalTrials.gov record · University of Chile

RecruitingNot a traditional drug phaseKütahya, Turkiye
Not a traditional drug phase: Pain classification method for Multiple Sclerosis

This watch-and-measure (no experimental treatment required) cross-sectional study aims to determine chronic pain phenotypes in individuals with multiple sclerosis (MS) and to investigate the clinical characteristics associated with different pain phenotypes. Participants with MS and chronic pain will undergo a comprehensive clinical assessment to identify nociceptive, neuropathic, nociplastic, and mixed pain phenotypes.

NCT07766213 · Official ClinicalTrials.gov record · Kutahya Health Sciences University

RecruitingNot a traditional drug phaseXi'an, Shaanxi
Not a traditional drug phase: Unconscious Trauma Reactivation plus Eye Movements for Post-traumatic Stress Disorder (PTSD)

Post-Traumatic Stress Disorder (PTSD) and trauma-related symptoms are often characterized by recurrent intrusive memories that cause distress and interfere with daily functioning. Although trauma-focused interventions such as Eye Movement Desensitization and Reprocessing (EMDR) may be effective, they often involve engagement with trauma-related memories, which can be distressing for some individuals and may affect treatment acceptability.

NCT07767396 · Official ClinicalTrials.gov record · Shaanxi Normal University

RecruitingNot a traditional drug phaseSan Francisco, California
Validation of Biomarkers for Long COVID in the LIINC Viral Immunopathogenesis and Persistence Repeat Donor …

This study wants to better understand the biological changes associated with Long COVID and to identify laboratory tests (biomarkers) that may help diagnose the condition and measure how it changes over time. Researchers will enroll people with Long COVID as well as people who have fully recovered after COVID-19 infection.

NCT07770022 · Official ClinicalTrials.gov record · University of California, San Francisco

RecruitingPhase 4Ljubljana
Phase 4: testing Empagliflozin (Jardiance®) for Diabetes Type 2

The purpose of the study is to compare the effect of empagliflozin, metformin, and the combination of both on the oxidative capacity of skeletal muscle and its microvascular reactivity in individuals with newly diagnosed type 2 diabetes. As the primary outcome, the investigators selected the change in skeletal muscle oxidative capacity and posed the following scientific question: Does empagliflozin significantly improve the oxidative capacity of skeletal muscle?

NCT07771010 · Official ClinicalTrials.gov record · University Medical Centre Ljubljana

RecruitingPhase 3Bakersfield, California
Phase 3: testing tilrekimig for Asthma

The purpose of this clinical study is to learn about the safety and effects of the study medicine (called tilrekimig) for the potential treatment of severe asthma. Asthma is a condition that makes it challenging to breathe, which negatively impacts the quality of life of people who are affected.

NCT07772921 · Official ClinicalTrials.gov record · Pfizer

RecruitingNot a traditional drug phaseChapel Hill, North Carolina
Not a traditional drug phase: This study is observational. Only patients who have previously tested positive for SARS-CoV-2 infection or are experiencing ongoing symptoms. for SARS CoV-2 Post-Acute Sequelae

This study will examine how common Long COVID is and how symptoms may persist over time in people who have previously had COVID-19. Researchers will collect information about participants' health and symptoms through questionnaires and may collect saliva and other non-invasive oral samples.

NCT07781501 · Official ClinicalTrials.gov record · University of North Carolina, Chapel Hill

RecruitingPhase 2 / Phase 3Ottawa, Ontario
Phase 2 / Phase 3: testing Ketamine (0.5 mg/kg) for Treatment Resistant Depression

The goal of this clinical trial is to see if combining ketamine with behavioral activation (BA) therapy to treat moderate to severe treatment-resistant depression improves depressive symptoms and general functioning more than ketamine alone. We aim to find out whether participants who receive both treatments: 1.

NCT07801703 · Official ClinicalTrials.gov record · The Royal's Institute of Mental Health Research

RecruitingPhase 2Scottsdale, Arizona
Phase 2: testing VIM0423 for PARKINSON DISEASE (Disorder)

Vista PD is a randomly assigned, compared with a dummy treatment, multicenter study to measure the how well it works, PK, safety, and tolerability of VIM0423 in adults with Parkinson's disease tremor insufficiently responsive to dopaminergic therapy. The main objectives of this clinical trial are to determine the following: * Does VIM0423 therapy improve tremor symptoms in adults with Parkinson's disease?

NCT07804615 · Official ClinicalTrials.gov record · Vima Therapeutics

RecruitingNot a traditional drug phaseBeijing, Beijing Municipality
Not a traditional drug phase: Model-Guided Precision Acupuncture for Polycystic Ovary Syndrome

This study is designed as a prospective, multicenter, parallel-group randomly assigned controlled trial to measure the effectiveness of a "precision acupuncture + personalized lifestyle" intervention, guided by dynamic multimodal risk monitoring based on the four diagnostic methods of Traditional Chinese Medicine (TCM), in improving insulin resistance in patients with polycystic ovary syndrome (PCOS). Compared with "conventional acupuncture + standard lifestyle intervention," the study will primarily assess changes in the homeostatic model assessment of insulin resistance (HOMA-IR) after 12 weeks of treatment.

NCT07809503 · Official ClinicalTrials.gov record · Peking University Third Hospital

RecruitingNot a traditional drug phaseNew York, New York
Not a traditional drug phase: Reinforcement Learning (RL)-Based Personalized Exercise Recommendations for Pelvic Pain

WorkoutCPP is a pilot study evaluating the feasibility of a personalized exercise recommendation system for individuals with chronic pelvic pain disorders (CPPDs). The study uses reinforcement learning (RL), a type of artificial intelligence that adapts recommendations over time based on each participant's reported pain levels, symptom burden, and exercise compliance.

NCT07810218 · Official ClinicalTrials.gov record · Icahn School of Medicine at Mount Sinai

RecruitingNot a traditional drug phaseIsparta
Aerobic Fitness in Multiple Sclerosis: The Relationship Between Balance and Sensory Dual-Tasking

The aim of this study is to comparatively examine the effect of aerobic fitness levels on walking and balance performance, sensory dual-task (proprioceptive and vestibular) performance, balance confidence, and fatigue levels in individuals diagnosed with MS. Research hypotheses H1: MS patients with high aerobic fitness exhibit superior walking speed and balance performance compared to MS patients with low aerobic fitness.

NCT07815990 · Official ClinicalTrials.gov record · Suleyman Demirel University

RecruitingNot a traditional drug phasePeschiera del Garda, Verona
Not a traditional drug phase: Retrospective case-control analysis for Endometriosis

This study hypothesizes that the histological, immunophenotypic, and molecular characterization of atypical endometriotic lesions may be related to specific clinical and ultrasound features.Identifying potentially atypical lesions would allow for more accurate stratification of patients, distinguishing definitely benign from potentially atypical endometriosis. The targeted study of endometriosis, both typical and atypical, also with reference to the inflammatory microenvironment, as well as immunophenotypic and molecular characteristics, could allow the formulation of pathogenic hypotheses on the development and progression of atypia towards malignant neoplasms.

NCT07816133 · Official ClinicalTrials.gov record · Casa di Cura Dott. Pederzoli

RecruitingPhase 1Providence, Rhode Island
Phase 1: testing Psilocybin (Usona Institute) for Phase I

The primary aim of this phase I mechanistic pilot study is to measure the effects of psilocybin on aspects of cognition in healthy adult volunteers. Up to 24 participants will receive a single dose of either psilocybin or inert dummy treatment (placebo), and they will be asked to complete several computer-based behavioral tasks measuring features of learning, belief updating, and abstraction.

NCT07818564 · Official ClinicalTrials.gov record · Brown University

RecruitingNot a traditional drug phaseLund, Skåne County
Not a traditional drug phase: High Definition Brain Stimulation (HDBS) for Essential Tremor

The currently available treatments of Parkinson's disease (PD) and Essential Tremor (ET) are inadequate and accompanied by adverse side effects making the treatment much less effective. This includes treatments with pharmaceuticals as well as electrical brain stimulation (DBS; Deep Brain Stimulation).

NCT07820189 · Official ClinicalTrials.gov record · Lund University

RecruitingNot a traditional drug phaseBaltimore, Maryland
Imaging Assessment of Swallowing and Speech Muscles in Inclusion Body Myositis

This study will evaluate whether neuromuscular ultrasound and MRI can be used as imaging markers of bulbar involvement and swallowing dysfunction in individuals with inclusion body myositis (IBM). Researchers will compare imaging and clinical findings in participants with IBM with those in participants with other myopathies, ALS, PLS, and healthy volunteers.

NCT07823101 · Official ClinicalTrials.gov record · Johns Hopkins University

RecruitingNot a traditional drug phaseNantong, Jiangsu
Not a traditional drug phase: Digital Prevention Management for Ischemic Stroke

The goal of this study is to find out whether a comprehensive management program that uses a smart bracelet and a mobile app can help people who have had an ischemic stroke (a type of stroke caused by a blocked blood vessel in the brain) to prevent another stroke. The investigators also want to see whether this program helps with controlling blood pressure, blood sugar, and blood lipids, as well as with taking medications correctly, improving daily habits, and supporting emotional well-being.

NCT07825311 · Official ClinicalTrials.gov record · Affiliated Hospital of Nantong University

RecruitingPhase 2Los Angeles, California
Phase 2: testing Tirzepatide for Methamphetamine Use Disorder

This is a phase 2, randomly assigned, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment, parallel-group trial evaluating the tolerability, safety, and preliminary how well it works of tirzepatide for the treatment of individuals with moderate or severe methamphetamine use disorder (MtUD). The central hypothesis of the proposed research is that tirzepatide is a safe and potentially efficacious treatment of MtUD.

NCT07825857 · Official ClinicalTrials.gov record · University of Texas Southwestern Medical Center

RecruitingPhase 1The Bronx, New York
Phase 1: testing Lm-LLO-TT for Pancreas Cancer, Duct Cell Adenocarcinoma

ClinicalTrials.gov Brief Summary This Phase 1, open-label, first-in-human study is designed to measure the safety, tolerability, and recommended dose of intraperitoneal (IP) administration of Lm-LLO-TT in combination with low-dose gemcitabine in adults with previously treated, unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC). Lm-LLO-TT is a live attenuated Listeria monocytogenes-based immunotherapy engineered to express a tetanus toxoid antigen.

NCT07828236 · Official ClinicalTrials.gov record · Loki Therapeutics, Inc.

RecruitingNot a traditional drug phaseLondon
Exploring Factors Linked to Worsening Over Time in People With Early-stage Knee Osteoarthritis and Those Wi…

The goal of this watch-and-measure (no experimental treatment required), non-treatment cohort study is to identify tests or markers in blood or knee fluid, or any genetic risk factors that might contribute to worsening or improvement of knee osteoarthritis. Males and females aged ≥18 with early-stage knee osteoarthritis, prior proven acute knee injury, or degenerative meniscal tear will be recruited at Imperial College Healthcare NHS Trust.

NCT07833488 · Official ClinicalTrials.gov record · Imperial College London

RecruitingNot a traditional drug phaseMexico City, Mexico City
Body Composition Changes After Initiation of GLP-1 Receptor Agonists in Adults With Obesity or Type 2 Diabetes

Researchers want to understand what happens to muscle and fat in the body after adults with obesity and/or type 2 diabetes start taking a GLP-1 receptor agonist medication (GLP-1RA), a type of drug already approved and commonly prescribed for weight loss and blood sugar control. No experimental medication will be given.

NCT07835360 · Official ClinicalTrials.gov record · Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

RecruitingNot a traditional drug phaseSalt Lake City, Utah
Not a traditional drug phase: neck exoskeleton controller for Amyotrophic Lateral Sclerosis & Other Neuromuscular Disorders

The investigators will develop and evaluate controllers for a powered neck exoskeleton in patients with amyotrophic lateral sclerosis (ALS) to understand how to allow adequate personalization and function and achieves satisfaction from users. In this small device feasibility study, you would be enrolled from the ALS clinic at the University of Utah Hospital.

NCT07836751 · Official ClinicalTrials.gov record · University of Utah

RecruitingNot a traditional drug phaseBrescia, Brescia
Not a traditional drug phase: Transcranial Alternating Current Stimulation for Transcranial Alternating Current Stimulation

The aim of the study is to measure the clinical and biological how well it works, as well as predictors of how well it works, of a home-based intervention combining transcranial alternating current stimulation (tACS) with individualized computerized cognitive training in patients with mild Alzheimer's disease (AD). In neurodegenerative diseases, including AD, neurodegeneration is accompanied by alterations in brain oscillatory activity.

NCT07839650 · Official ClinicalTrials.gov record · IRCCS Centro San Giovanni di Dio Fatebenefratelli

RecruitingNot a traditional drug phaseBeijing, Beijing Municipality
Not a traditional drug phase: testing High-dose methotrexate-based therapy for Primary Central Nervous System Lymphoma (PCNSL)

This project aims to establish and prospectively register a longitudinal, multimodal biobank for primary central nervous system lymphoma (PCNSL). The study will primarily enroll patients undergoing needle biopsy or surgical resection of lesions involving the brain, spinal cord, or meninges, with a pathological diagnosis of central nervous system lymphoma.

NCT07842835 · Official ClinicalTrials.gov record · Xiaohui Ren

RecruitingNot a traditional drug phasePhiladelphia, Pennsylvania
Developing New Ways to Detect Respiratory Impairment Early in ALS

The goal of this watch-and-measure (no experimental treatment required) study is to develop new ways to detect early changes associated with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. The study will examine whether changes in breathing, magnetic resonance imaging (MRI) of the brainstem and spinal cord, and blood markers can identify early signs of ALS before major physical changes occur.

NCT07844590 · Official ClinicalTrials.gov record · Thomas Jefferson University

RecruitingNot a traditional drug phaseIrvine, California
Not a traditional drug phase: Motion Perception Task for SCHIZOPHRENIA 1 (Disorder)

In Study 1, investigators will test the ability of each of the seven paradigms to differentiate between schizophrenia (SZ)/schizoaffective disorder (SZA) and matched healthy control subjects (HC) and to predict individual differences in clinical measures of hallucinations and delusions (as well as measures of function). Investigators will also directly compare the tasks in terms of predictive ability and psychometric properties and determine whether the tasks share variance or explain unique variance.

NCT07853807 · Official ClinicalTrials.gov record · Washington University School of Medicine

RecruitingNot a traditional drug phaseIstanbul, Kucukcekmece
Not a traditional drug phase: testing GLP-1 receptor agonist (e.g., semaglutide, tirzepatide) - prescribed by the treating physician as standard care; the study does not assign or alter treatment. for Obesity

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual GLP-1/GIP agonists such as semaglutide and tirzepatide produce marked weight loss in people with obesity, with reported reductions of about 15-20%. Rapid weight loss may reduce not only fat mass but also lean body mass and skeletal muscle mass, raising concern about sarcopenia and sarcopenic obesity.

NCT07858864 · Official ClinicalTrials.gov record · Istanbul Saglik Bilimleri University

RecruitingNot a traditional drug phaseHuai'an, Jiangsu
Not a traditional drug phase: testing DEX 0.2 μg/kg/h. for Uterine Fibroids (Leiomyoma)

Study Objectives This study aims to investigate the effects of preoperative stellate ganglion block and intraoperative intravenous dexmedetomidine on postoperative sleep disturbance in patients undergoing laparoscopic gynecologic surgery, with the goals of reducing pain and postoperative adverse reactions and identifying an effective, safe, economical, and broadly applicable intervention strategy that may facilitate emergence from anesthesia, accelerate postoperative recovery, shorten the length of hospital stay, and reduce hospitalization costs. This trial aims to determine whether preoperative stellate ganglion block (SGB) and intraoperative intravenous dexmedetomidine (DEX) can improve postoperative sleep quality in patients undergoing laparoscopic gynecologic surgery, and whether the combination of these two interventions provides an interaction effect or additional ben

NCT07860203 · Official ClinicalTrials.gov record · Catherin Zhang

RecruitingNot a traditional drug phaseRochester, Minnesota
Not a traditional drug phase: MagVenture TMS Therapy System with Localite Navigation System and actiCHamp EEG for Major Depressive Disorder (MDD)

The purpose of this research is to see if an experimental treatment for depression called intermittent theta burst stimulation (iTBS), a form of transcranial magnetic stimulation (TMS) can be improved for better results using electroencephalography (EEG) recordings (brain waves) for individuals with Major Depressive Disorder (major depression). This is a feasibility study to test a "closed-loop" procedure which guides the timing of this FDA-cleared form of TMS.

NCT07862205 · Official ClinicalTrials.gov record · Mayo Clinic

RecruitingPhase 1 / Phase 2Ann Arbor, Michigan
Phase 1 / Phase 2: testing Tributyrin for Parkinson Disease

This research is studying a supplement called tributyrin in people with Progressive Supranuclear Palsy (PSP) to learn about its whether it is safe and how hard side effects are to live with as a potential treatment. The goal of this research study is to see if a similar supplementation regimen and virtual testing is feasible for people with PSP.

NCT07863180 · Official ClinicalTrials.gov record · Prabesh Kanel

RecruitingNot a traditional drug phaseMoscow
Not a traditional drug phase: testing Tirzepatide for Class I Obesity

This single-center randomly assigned comparative study is designed to compare the effectiveness of tirzepatide and transcutaneous low-frequency auricular vagus nerve stimulation in adults with class I obesity and without chronic non-communicable diseases. The study focuses on changes in body weight, anthropometric indices, epicardial and visceral adipose tissue, body composition, behavioral factors, skeletal muscle characteristics, and cardiac structure and function.

NCT07866183 · Official ClinicalTrials.gov record · National Medical Research Center for Therapy and Preventive Medicine

RecruitingPhase 3River Forest, Illinois
Phase 3: testing tilrekimig for Asthma

The purpose of this clinical study is to learn about the safety and effects of the study medicine (called tilrekimig) for the potential treatment of severe asthma. Asthma is a condition that makes it challenging to breathe, which negatively impacts the quality of life of people who are affected.

NCT07869043 · Official ClinicalTrials.gov record · Pfizer

RecruitingNot a traditional drug phaseBosisio Parini, Lecco
Not a traditional drug phase: Immersive Virtual Reality Embodiment Manipulations for Spinal Cord Injury

Embodiment is an important aspect of virtual reality because it affects how natural and engaging the experience feels and can influence performance and learning in VR-based applications, including rehabilitation. In VR, embodiment refers to the extent to which a person feels that a virtual body (avatar) is their own and under their control.

NCT07870044 · Official ClinicalTrials.gov record · IRCCS Eugenio Medea

RecruitingNot a traditional drug phaseIstanbul
Relationship Between Interoception and Postural Control in Constipation-Predominant Irritable Bowel Syndrome

This cross-sectional, watch-and-measure (no experimental treatment required), controlled comparative study aims to investigate the relationship between interoception and postural control in individuals with constipation-predominant irritable bowel syndrome (IBS-C) and to compare the findings with those of healthy individuals. Interoception will be assessed using the Multidimensional Assessment of Interoceptive Awareness-2 (MAIA-2), postural characteristics will be evaluated using the Corbin Posture Analysis, and stool type in the IBS-C group will be assessed using the Bristol Stool Scale.

NCT07870915 · Official ClinicalTrials.gov record · Saglik Bilimleri Universitesi

RecruitingPhase 3Hialeah Gardens, Florida
Phase 3: testing Ensifentrine for Pulmonary Disease, Chronic Obstructive

This study wants to measure the how well it works and safety of ensifentrine (MK-5884) compared with dummy treatment (placebo) for the prevention of moderate and severe COPD exacerbation in adults with COPD and a history of exacerbations while receiving SOC treatment. The study will also measure the how well it works of ensifentrine compared with dummy treatment (placebo) in improving lung function, improving health related quality of life, and preventing severe exacerbations.

NCT07874815 · Official ClinicalTrials.gov record · Merck Sharp & Dohme LLC

RecruitingNot a traditional drug phaseBeijing, Beijing Municipality
Not a traditional drug phase: testing Compound methoxyphenamine capsules for Paroxysmal Atrial Fibrillation

This prospective, multicenter, randomly assigned, controlled, noninferiority trial will compare local anesthesia with conscious sedation and general anesthesia in patients undergoing pulsed field ablation for paroxysmal atrial fibrillation. A total of 390 participants aged 18 to 80 years will be randomly assigned in a 1:1 ratio to undergo pulsed field ablation under either local anesthesia with conscious sedation or general anesthesia.

NCT07877519 · Official ClinicalTrials.gov record · China National Center for Cardiovascular Diseases

RecruitingNot a traditional drug phaseBalıkesir
Preoperative Multimorbidity and Functional Recovery After Total Knee Arthroplasty

This prospective watch-and-measure (no experimental treatment required) cohort study aims to investigate the association between preoperative multimorbidity burden and functional recovery after primary total knee arthroplasty (TKA) in patients with knee osteoarthritis. Approximately 230 adult patients undergoing elective unilateral primary TKA will be enrolled at a single hospital in Türkiye.

NCT07882316 · Official ClinicalTrials.gov record · Balikesir Ataturk City Hospital

RecruitingNot a traditional drug phaseNew York, New York
Parkinson's Disease in Type 1 Gaucher Disease

Parkinson's disease (PD) is an age-related movement disorder with a complex pathophysiology. Among the risk factors for PD, variants in beta-glucocerebrosidase (encoded by the gene GBA1) represent one of the most significant heritable risk factors for lifetime PD risk.

NCT07886879 · Official ClinicalTrials.gov record · Icahn School of Medicine at Mount Sinai

RecruitingNot a traditional drug phaseIstanbul, Göztepe
Not a traditional drug phase: Physical Activity Education for Obstructive Sleep Apnea

Although exercise and physical activity have shown beneficial effects in individuals with obstructive sleep apnea (OSA), evidence regarding the effects of daily physical activity habits on sleep quality and respiratory parameters remains limited. This study aims to investigate these associations in individuals with OSA.

NCT07889154 · Official ClinicalTrials.gov record · Medipol University

RecruitingPhase 1 / Phase 2Hangzhou, None Selected
Phase 1 / Phase 2: whey protein powder for Alcohol-associated Fatty Liver Disease

Alcohol-associated liver disease (ALD) is a major cause of mortality from advanced liver disease, accounting for 47.9% of cirrhosis-related deaths and 30% of hepatocellular carcinoma-related deaths annually. In China, both per capita alcohol consumption and the prevalence of ALD (approximately 5.15%) are on the rise, making ALD an increasingly significant public health burden.

NCT07897981 · Official ClinicalTrials.gov record · Li Lab,MD

RecruitingNot a traditional drug phaseBerlin, State of Berlin
Not a traditional drug phase: Standard of Care (Investigator Choice) for ALS (Amyotrophic Lateral Sclerosis)

This watch-and-measure (no experimental treatment required) registry collects existing medical and routine care data from people with amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), and other motor system disorders. The registry includes information about disease course, functional abilities, medications, medical devices, therapeutic services, nutrition, breathing support, and nursing care.

NCT07900672 · Official ClinicalTrials.gov record · Ambulanzpartner Soziotechnologie APST GmbH

RecruitingNot a traditional drug phaseEastbourne
Not a traditional drug phase: testing Deep sedation with midazolam and fentanyl or midazolam and remifentanil for Atrial Fibrillation (AF)

Pulsed Field Ablation (PFA) has created a 'paradigm shift' within cardiac electrophysiology and the initial experience demonstrates that PFA is safe, rapid and effective compared to both radiofrequency ablation and cryoablation in atrial fibrillation (AF). Presently, AF ablation procedures in the UK using PFA are routinely performed using general anaesthetic (GA) support requiring an anaesthetist and ODP being present in all procedures.

NCT07900685 · Official ClinicalTrials.gov record · East Sussex Healthcare NHS Trust

RecruitingNot a traditional drug phaseReggio Emilia
KLF4 Epigenetic Modulation

The study investigates the epigenetic regulation of KLF4 during the progression from colorectal polyps to adenomas and carcinomas. Quantitative KLF4 methylation will be assessed in colorectal tissue samples obtained during routine colonoscopy, together with KLF4 gene expression and its correlation with methylation status in matched tissue samples.

NCT07901335 · Official ClinicalTrials.gov record · Azienda USL Reggio Emilia - IRCCS

RecruitingNot a traditional drug phaseVan
Not a traditional drug phase: testing GLP-1 Receptor Agonist Therapy for Obesity & Overweight

This watch-and-measure (no experimental treatment required) study will compare weight loss over two years in adults receiving GLP-1 receptor agonist medications with weight loss in adults who previously underwent laparoscopic sleeve gastrectomy, an operation that reduces the size of the stomach. Adults starting GLP-1 medications as part of their usual care will be followed for 24 months.

NCT07901777 · Official ClinicalTrials.gov record · Yuzuncu Yil University

RecruitingNot a traditional drug phaseRawalpindi, Punjab Province
Not a traditional drug phase: no active ingredient for SLE - Systemic Lupus Erythematosus

Systemic lupus erythematosus (SLE) is a complex autoimmune disorder that affects individuals globally, yet there is a significant lack of data regarding its prevalence and management, particularly in Asian populations like Pakistan. To address this gap, we are initiating a groundbreaking project to establish a Lupus Registry in Pakistan.

NCT07902622 · Official ClinicalTrials.gov record · Foundation University Islamabad

RecruitingNot a traditional drug phaseHangzhou, Zhejiang
A Prospective Study of Anxiety, Depression, and Bipolar Disorder in People

This study aims to understand how anxiety disorders, depressive disorders, and bipolar disorder change over time and to identify patterns that may help with earlier recognition, diagnosis, and prediction of future symptoms. The study will enroll approximately 2,690 participants aged 12 to 55 years across multiple hospitals in China.

NCT07903246 · Official ClinicalTrials.gov record · Second Affiliated Hospital, Zhejiang University, School of Medicine

RecruitingNot a traditional drug phaseHamburg
Not a traditional drug phase: testing Abrocitinib for Atopic Dermatitis

Atopic dermatitis is a chronic inflammatory skin disease associated with intense pruritus, recurrent eczematous lesions, sleep disturbance, and reduced quality of life. The disease may be influenced by genetic factors, environmental triggers, epidermal barrier dysfunction, and immune dysregulation.

NCT07904546 · Official ClinicalTrials.gov record · Universitätsklinikum Hamburg-Eppendorf

RecruitingNot a traditional drug phaseBeijing, Beijing Municipality
Development and Clinical Validation of Artificial Intelligence Algorithms for Sleep Staging and Obstructive…

In recent years, wearable and contactless devices, including smart rings, smart bands/watches, and smart mattresses, have developed rapidly and can continuously collect multidimensional data such as heart rate, oxygen saturation, respiration, body movement, snoring, body temperature, and environmental parameters. Nevertheless, most current consumer-grade or wellness-oriented devices have not been trained and validated using large polysomnography (PSG)-synchronized reference datasets.

NCT07908160 · Official ClinicalTrials.gov record · Peking University First Hospital

RecruitingNot a traditional drug phaseAntwerp
Multi-biomarkers in DEE

Developmental and Epileptic Encephalopathies (DEEs) with a genetic cause represent a complex group of neurodevelopmental disorders characterized by intellectual disability and drug-resistant epilepsy. Because targeted, disease-modifying precision therapies like gene replacement and antisense oligonucleotides are rapidly approaching clinical trials, establishing objective diagnostic, prognostic, and therapeutic biomarkers is an urgent priority.

NCT07909382 · Official ClinicalTrials.gov record · Istituto Giannina Gaslini

RecruitingNot a traditional drug phaseBeijing, Beijing Municipality
Construction and Validation of an Impulse Oscillometry (IOS)-Based Platform for Screening, Diagnosis, and M…

This is a multicenter, watch-and-measure (no experimental treatment required) study aiming to construct and validate an Impulse Oscillometry (IOS)-based platform for the screening, diagnosis, and management of chronic airway diseases (COPD and asthma). Phase 1 is a cross-sectional study to build and validate diagnostic models for COPD and asthma using IOS parameters, with respiratory specialists' clinical diagnosis as the gold standard.

NCT07910409 · Official ClinicalTrials.gov record · Beijing Chao Yang Hospital

RecruitingNot a traditional drug phaseSan Francisco, California
Not a traditional drug phase: Target systolic blood pressure <120 mmHg. for End Stage Kidney Disease (ESKD)

The GOAL-BP pilot study will help determine whether a study comparing two blood pressure goals can be carried out in adults with end-stage kidney disease and high blood pressure who receive peritoneal dialysis. The main questions it aims to answer are whether eligible patients can be recruited for the study.

NCT07910773 · Official ClinicalTrials.gov record · University of California, San Francisco

RecruitingNot a traditional drug phaseIstanbul, Uskudar
Not a traditional drug phase: Inspiratory Muscle Training for Generalized Anxiety Disorder (GAD)

This study will compare inspiratory muscle training and diaphragmatic breathing exercises in individuals with generalized anxiety disorder (GAD). It aims to see if adding either breathing-based intervention to a combined exercise program improves anxiety symptoms and other health-related outcomes compared with adding progressive muscle relaxation.

NCT07913503 · Official ClinicalTrials.gov record · Saglik Bilimleri Universitesi

RecruitingNot a traditional drug phaseCambridge, Cambridgeshire
Not a traditional drug phase: testing Anifrolumab for Systemic Lupus Erythematosus

People with systemic lupus erythematous (SLE) have an increased risk of premature atherosclerotic cardiovascular disease, which is believed to be caused by arterial inflammation. The aim of this study is to investigate the effects an interferon-targeting drug (anifrolumab) used for the treatment of active SLE on arterial inflammation.

NCT07913919 · Official ClinicalTrials.gov record · University of Cambridge

RecruitingNot a traditional drug phaseGujrat, Punjab Province
Not a traditional drug phase: testing Vitamin D3 for Irritable Bowel Syndrome (IBS)

This study was designed to determine whether vitamin D supplementation improved symptoms in children with irritable bowel syndrome, a condition associated with repeated abdominal pain and changes in bowel habits. It was hypothesized that vitamin D supplementation would reduce symptom severity and increase blood vitamin D levels compared with dummy treatment (placebo).

NCT07914478 · Official ClinicalTrials.gov record · Aziz Bhatti Shaheed Teaching Hospital

RecruitingNot a traditional drug phaseHangzhou, Zhejiang
Not a traditional drug phase: Endoscopy-assisted breast-conserving surgery (SRRSHzb-EABCS) for Breast Cancer

This multicenter, open-label, prospective, randomly assigned controlled study compares a novel endoscopy-assisted breast-conserving surgery technique (SRRSHzb-EABCS) with conventional open breast-conserving surgery (CBCS) in women with breast cancer who wish to preserve their breast. Breast-conserving surgery followed by radiotherapy is a standard treatment for early-stage breast cancer.

NCT07920094 · Official ClinicalTrials.gov record · Sir Run Run Shaw Hospital

RecruitingNot a traditional drug phaseVilnius
Not a traditional drug phase: Immersive Virtual Reality Walking Conditions for Knee Osteoarthritis

Knee osteoarthritis (KOA) is a common musculoskeletal condition associated with pain, impaired physical function, and movement-related fear. Psychological factors, particularly fear of movement (kinesiophobia), may influence movement behavior and limit participation in physical activity and exercise therapy.

NCT07920120 · Official ClinicalTrials.gov record · University of Primorska

RecruitingNot a traditional drug phaseParis
Cohort of Women Living With HIV-1 and Receiving Bictegravir/Emtricitabine/Tenofovir Alafenamide

Biktarvy® is a widely prescribed antiretroviral (ARV) medication used for the treatment of HIV-1, formulated as a single-tablet regimen. This combination therapy consists of three potent antiretroviral drugs: bictegravir (BIC/B), an integrase strand transfer inhibitor (INSTI); emtricitabine (FTC/F), a nucleoside reverse transcriptase inhibitor (NRTI); and tenofovir alafenamide (TAF), the novel prodrug of tenofovir, another NRTI.

NCT07921472 · Official ClinicalTrials.gov record · Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida

RecruitingNot a traditional drug phaseKuala Lumpur, Kuala Lumpur
Not a traditional drug phase: Broad-spectrum multivitamin and mineral supplementation for Attention Deficit Hyperactivity Disorder (ADHD)

Attention-deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental condition in children that can affect attention, behavior, learning, and daily functioning. Nutritional status, gut health, and sleep and circadian patterns may influence ADHD-related symptoms.

NCT07922252 · Official ClinicalTrials.gov record · UCSI University

RecruitingPhase 4Ljubljana
Phase 4: testing Lidocaine HCl 1% for Head and Neck Cancer (H&N)

This study aims to see if different doses of locally infiltrated lidocaine affect inflammation, neurological biomarkers, and cognitive function in patients undergoing major head and neck cancer surgery. Major head and neck cancer surgery can cause substantial physical stress, inflammation, and changes in cognitive function after surgery.

NCT07922759 · Official ClinicalTrials.gov record · University Medical Centre Ljubljana

RecruitingNot a traditional drug phaseNew Taipei City, New Taipei City
Development and Validation of a Multimodal Deep Learning Model Using Peripheral Oxygen Saturation and Balli…

Obstructive sleep apnea (OSA) is a common sleep disorder associated with cardiovascular, metabolic, and neurocognitive complications. The standard diagnostic test for OSA is in-laboratory polysomnography (PSG), which can be costly, labor-intensive, and inconvenient for repeated or large-scale screening.

NCT07923825 · Official ClinicalTrials.gov record · Fu Jen Catholic University

RecruitingNot a traditional drug phaseLeuven
Not a traditional drug phase: Standard of care (no study intervention) for Stroke

Stroke is a leading cause of death and adult disability. Stroke care is still limited by fragmented care pathways, non-standardised diagnostic work-up and follow-up, and local, non-interoperable data systems across the pre-hospital, in-hospital and post-hospital settings.

NCT07924371 · Official ClinicalTrials.gov record · Hospital Universitari Vall d'Hebron Research Institute

RecruitingNot a traditional drug phaseLondon
Chronic Respiratory Disease Participant Engagement Study

This study is designed for adults who have, or suspected to have, a long-term respiratory (lung) condition such as Alpha-1 Antitrypsin Deficiency (AATD), chronic obstructive pulmonary disease (COPD), asthma, bronchiectasis, or interstitial lung disease (ILD). The aim of the study is to help participants become familiar with the clinical trials unit environment and research team before deciding whether they would like to take part in future clinical trials.

NCT07924462 · Official ClinicalTrials.gov record · Richmond Research Institute

RecruitingNot a traditional drug phaseBrussels, Belgium
Not a traditional drug phase: Emotional Reactivity Experimental Protocol for Alcohol Use Disorder

The goal of this watch-and-measure (no experimental treatment required) study is to investigate emotional recognition and emotional reactivity in individuals with severe Alcohol Use Disorder (sAUD), Major Depressive Disorder (major depression), comorbid sAUD and depressive symptoms (sAUD+DS), and healthy controls. The main questions this study aims to answer are: * Do individuals with sAUD, major depression, sAUD+DS, and healthy controls exhibit different patterns of emotional recognition and emotional reactivity in response to dynamic emotional stimuli?

NCT07925281 · Official ClinicalTrials.gov record · Université Catholique de Louvain

RecruitingNot a traditional drug phaseNairobi
Not a traditional drug phase: HPV DNA Testing (Abbott Alinity m HPV Assay) for Human Papillomavirus (HPV)

The overall goal of this study is to inform the design and establish feasibility for a future clinical trial to determine the optimal management of women living with HIV (WLWH) with high-risk human papillomavirus (hrHPV) detected on HPV-based cervical cancer screening. WLWH have a higher diversity of anogenital HPV types causing cervical high-grade squamous intraepithelial lesions (hHSIL) and invasive cancer compared to women without HIV.

NCT07925307 · Official ClinicalTrials.gov record · University of California, San Diego

RecruitingNot a traditional drug phasePhoenix, Arizona
Not a traditional drug phase: fulvic acid for Metabolic Syndrome

Fulvic acid is a naturally occurring compound derived from the decomposition of organic matter in soil over long periods. Fulvic acid complexes, such as MLG-50 (MLG-50® Mineral Logic, Kalamazoo, Michigan), offer a highly concentrated, water-soluble form of fulvic acid that contains over 70 trace minerals and elements.

NCT07927283 · Official ClinicalTrials.gov record · Arizona State University

RecruitingNot a traditional drug phasePhoenix, Arizona
Not a traditional drug phase: Vinegar for Heartburn

In this study, a popular home remedy, vinegar, will be tested for its how well it works to relieve the discomfort of heartburn possibly by inducing the esophageal clearing mechanisms. We plan to recruit 22 individuals who report regular heartburn, but not diagnosed with erosive reflux disease, for this randomly assigned crossover trial.

NCT07927296 · Official ClinicalTrials.gov record · Arizona State University

RecruitingNot a traditional drug phaseBaltimore, Maryland
Not a traditional drug phase: testing TachoSil® for Cerebrospinal Fluid (CSF) Leak

This retrospective watch-and-measure (no experimental treatment required) cohort study compares the effectiveness and safety of added on top of your current treatment TachoSil® fibrin sealant patch with DuraSeal® hydrogel sealant for supporting dural sealing in adult patients undergoing cranial or spinal surgery at participating United States hospitals. Medical records will be reviewed to assess clinically evident cerebrospinal fluid leak or clinically evident pseudomeningocele within 90 days after surgery.

NCT07927413 · Official ClinicalTrials.gov record · Corza Medical GmbH

RecruitingNot a traditional drug phaseAtlanta, Georgia
Not a traditional drug phase: Treadmill-integrated virtual reality gait training for Multiple Sclerosis

This study will test whether a treadmill-based virtual reality walking program is safe, practical, and helpful for people with multiple sclerosis (MS). Participants will complete a 6-week training program and wear smart socks that measure how they walk before, during, and after the program.

NCT07927439 · Official ClinicalTrials.gov record · Shepherd Center, Atlanta GA

RecruitingNot a traditional drug phaseKüçükçekmece, Istanbul
Not a traditional drug phase: Ultrasound-Guided Thoracolumbar Fascia Injection for Chronic Low Back Pain

This prospective, randomly assigned, controlled clinical trial aims to measure the how well it works of ultrasound-guided thoracolumbar fascia (TLF) injection as an adjunct to standard conservative treatment in patients with type 2 diabetes mellitus and chronic nonspecific low back pain. A total of 60 patients aged 18-65 years, diagnosed with type 2 diabetes mellitus for at least one year and experiencing chronic nonspecific low back pain for at least three months, will be enrolled.

NCT07927530 · Official ClinicalTrials.gov record · Hatice Zehra FERHATLAR

RecruitingPhase 1Beijing, Beijing Municipality
Phase 1: testing CD19-Targeted In Vivo CAR-T Injection (first infusion, Day 0); CD22 -Targeted In Vivo CAR-T Injection (second infusion, Day 7) for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

This is a single-center, open-label, single-arm, prospective, investigator-initiated dose-escalation study to measure the safety, tolerability, preliminary how well it works, and cellular kinetics of an in vivo CAR-T cell immunotherapy targeting CD19 sequentially followed by CD22, in patients with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL). The investigational product is a targeted lentiviral vector that transduces the patient's endogenous T/NK cells in situ; no leukapheresis, ex vivo manufacturing, or lymphodepleting conditioning is required.

NCT07927816 · Official ClinicalTrials.gov record · Liping Dou

RecruitingNot a traditional drug phaseNilufer, Bursa
Not a traditional drug phase: Ultrasound-Guided Serratus Posterior Superior Intercostal Plane Block for Postoperative Pain

This study compares two ultrasound-guided nerve block techniques for pain control after mastectomy for breast cancer: the pectoral nerve block (PECS II) and the serratus posterior superior intercostal plane (SPSIP) block. Both techniques involve injecting local anesthetic near nerves supplying the surgical area.

NCT07929090 · Official ClinicalTrials.gov record · Bursa City Hospital

RecruitingNot a traditional drug phaseSeoul
Observational Study to Evaluate the Safety and Efficacy of Kremezin IDT/Fine Gran in Progressive Chronic Ki…

This study will be conducted under routine clinical practice in adults diagnosed with advanced chronic renal failure for whom treatment with Kremezin immediate-release tablets or Kremezin fine granules has been determined as part of standard clinical care. Kremezin will be prescribed and administered in accordance with the approved product labeling.

NCT07930169 · Official ClinicalTrials.gov record · HK inno.N Corporation

FAQ: ALS trials

How do I find recruiting ALS clinical trials?

This hub lists 584 recruiting ALS studies from a ClinicalTrials.gov snapshot, rewritten in plain English. Each card links to its NCT record. You can also search the official registry for “amyotrophic lateral sclerosis” at https://clinicaltrials.gov/search?cond=amyotrophic%20lateral%20sclerosis.

What does a ALS trial page on PlainTrials include?

A phase explainer, a plain-English summary grounded in the brief summary, inclusion/exclusion extracted from the public eligibility block, sponsor name, and any central contact the sponsor published. It is not a match to a trial.

Where are ALS studies located in this snapshot?

Sites that appear on these records include New York, New York; Seoul, South Korea; Madrid, Spain; Houston, Texas; Bethesda, Maryland. A city on a record is not a guarantee that the site is taking new patients this week — call the NCT contact.

Can PlainTrials tell me if I qualify for a ALS study?

No. Eligibility is decided by the study team using the protocol, labs, and consent. Our “who it is for” list is a readable extract of public inclusion text only.

Related brain and nerve hubs